UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: November 7, 2023
Commission File Number: 001-39777
NANOBIOTIX S.A.
(Exact Name of Registrant as Specified in its Charter)
60 Rue de Wattignies
75012 Paris, France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
This Report on Form 6-K, including the exhibits, shall be deemed to be incorporated by reference in the registration statement of Nanobiotix S.A. on
Form F-3 (File No. 333-262545) and Form S-8 (File Nos. 333-253062, 333-257239 and 333-272947), to the extent not superseded by documents or reports subsequently filed.
Information contained in this Report
On November 2, 2023, Nanobiotix S.A. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC,
Leerink Partners LLC and Guggenheim Securities, LLC, as representatives (“Representatives”) of the several underwriters named therein, relating to (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share,
€0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe
(including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. Pursuant to
the Underwriting Agreement, the Company also granted the underwriters an option to purchase up to an additional 839,869 ADSs, each representing one Ordinary Share, in the United States, at an offering price of $5.36 per ADS (the “U.S. Over-Allotment
Option”), and on November 3, 2023, the Representatives exercised the U.S. Over-Allotment Option to purchase an additional 680,000 ADSs, each representing one Ordinary Share, of the Company at an offering price of $5.36 per ADS (the “U.S. Option
Exercise”).
The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.” The Global Offering, including the U.S. Option
Exercise, is expected to close on November 7, 2023, subject to the satisfaction of customary closing conditions.
The Global Offering was made pursuant to a prospectus supplement dated November 2, 2023 to the base prospectus dated February 16, 2022, included in
the Company’s shelf registration statement on Form F-3 (File No. 333-262545), which was filed on February 4, 2022 and became effective on February 16, 2022.
In the Underwriting Agreement, the Company makes customary representations, warranties and covenants and also agrees to indemnify the underwriters
against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities.
The foregoing description of the Underwriting Agreement does not purport to be a complete description of the rights and obligations of the parties
thereunder, and is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Report on Form 6-K and incorporated by reference herein.
The legal opinion of Jones Day relating to the Ordinary Shares is filed as Exhibit 5.1 to this Report on Form 6-K and incorporated by reference
herein and a consent relating to the incorporation of such opinion is filed as Exhibit 23.1 by reference to its inclusion within Exhibit 5.1 and incorporated by reference herein.
In addition, pursuant to an existing securities purchase agreement, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) was obligated to
subscribe, subject to any required regulatory approvals for $25.0 million of the Company’s Ordinary Shares (in the form of restricted ADSs) (the “Placement Amount”), at a price per ADS equal to the public offering price of $5.36 per ADS in the U.S.
Offering in a concurrent private placement, exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to French foreign investment control rules, the Placement Amount was reduced, such that
JJDC has initially subscribed for 3,762,923 restricted ADSs (representing, together with JJDC’s existing stake, 9.99% of the outstanding voting rights of the Company’s capital stock (the “Regulatory Cap”), prior to the U.S. Option Exercise) for $20.2
million. Upon, and subject to, the approval of the French Ministry of Economy, JJDC will subscribe for 901,256 additional restricted ADSs (corresponding to the portion of the Placement Amount in excess of the Regulatory Cap) for $4.8 million. The
securities issued to JJDC will be issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act. The closing in respect of the initial 3,762,923 restricted ADSs is expected to occur on November 9, 2023, subject to
consummation of the U.S. Offering and the European Offering.
This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
| |
NANOBIOTIX S.A. |
| |
(Registrant) |
| |
|
|
| November 7, 2023 |
By: |
/s/ Bart Van Rhijn |
| |
|
Bart Van Rhijn |
| |
|
Chief Financial Officer |
Exhibit 1.1
NANOBIOTIX S.A.
(a société anonyme incorporated under the laws of France)
2,492,223 Ordinary Shares and
3,106,907 American Depositary Shares,
Each Representing One (1) Ordinary Share
(Nominal Value €0.03 Per Share)
UNDERWRITING AGREEMENT
November 2, 2023
JEFFERIES LLC
LEERINK PARTNERS LLC
GUGGENHEIM SECURITIES, LLC
As Representatives of the several Underwriters
c/o JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
c/o LEERINK PARTNERS LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
c/o GUGGENHEIM SECURITIES, LLC
330 Madison Avenue, 12th Floor
New York, New York 10017
Ladies and Gentlemen:
Nanobiotix S.A., a société anonyme incorporated under the laws
of France and registered with the Registre du Commerce et des Sociétés of Paris under number 447 521 600 00034 (the “Company”), proposes to issue and sell to the several underwriters (the “Underwriters”) all named in Schedule
A, an aggregate of (i) 2,492,223 ordinary shares, nominal value €0.03 per share (the “Ordinary Shares”) of the Company (the “Firm Shares”) and (ii) Ordinary Shares to be delivered in the form of an aggregate of 3,106,907 American
Depositary Shares (“ADSs”), each representing one Ordinary Share (the “Firm ADSs” and, together with the Firm Shares, the “Firm Securities”), as set forth in Schedule A hereto. The Company also grants to the Underwriters,
acting severally and not jointly, the option described in Section 2 hereof to purchase all or any part of 839,869 additional Ordinary Shares to be delivered in the form of ADSs (the “Option ADSs”), with each Option ADS representing one
Ordinary Share. The Firm ADSs and Option ADSs are collectively called the “Offered ADSs”. The aforesaid Firm Securities and all or any part of the Option ADSs subject to the option described in Section 2 hereof are herein collectively called
the “Offered Securities.” Unless the context otherwise requires, each reference to the Firm ADSs or the Option ADSs herein also includes the Ordinary Shares underlying the ADSs (the “Underlying Shares”).
Each of the parties acknowledges and agrees (for itself and on behalf of
its respective controlled Affiliates and persons acting on their behalf) that (i) the Offered Securities will be issued by way of one capital increase without preferential rights for existing shareholders reserved to categories of investors, pursuant
to the 24th, 26th and 29th resolutions of the Company’s combined general shareholders’ meeting held on June 27, 2023 and in accordance with Article L. 225-138 of the French Commercial Code and (ii) each prospective investor of Offered Securities shall have
executed an investor letter set forth as Exhibit G-1 or Exhibit G-2 hereto, as applicable, attesting in particular their qualification in the categories.
Jefferies LLC (“Jefferies”), Leerink Partners LLC (“Leerink
Partners”) and Guggenheim Securities, LLC (“Guggenheim”) have agreed to act as representatives of the several Underwriters (in such capacity, together the “Representatives”) in connection with the offering and sale of the Offered
Securities. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean you, as Underwriters, and the term “Underwriters” shall mean either the singular or the plural, as the
context requires. It is understood that the obligations of the Underwriters contained in this Agreement shall not constitute a performance guarantee (garantie de bonne fin) within the meaning of Article L. 225-145 of the French Commercial
Code.
The ADSs will be evidenced by American Depositary Receipts (the “ADRs”)
to be issued pursuant to a deposit agreement dated as of December 15, 2020 (the “Deposit Agreement”), among the Company, Citibank, N.A., as depositary (the “Depositary”), and the holders from time to time of the ADRs evidencing the ADSs
issued thereunder. The Company shall, following subscription by the Underwriters of the Firm ADSs and, if applicable, the Option ADSs, deposit, on behalf of the Underwriters, the Underlying Shares represented by such ADSs with Citibank, N.A., as
custodian (the “Depositary Custodian”) for the Depositary, which shall deliver such ADSs to the Representatives with respect to the U.S. Offering for the account of the several Underwriters for subsequent delivery to the other several
Underwriters or the investors, as the case may be.
The Company understands that the Underwriters propose to make a public
offering in the United States of the Offered Securities limited to investors falling within the categories of investors defined in the 24th resolution of the Company’s
general shareholders’ meeting held on June 27, 2023 (the “U.S. Offering”) as soon as the Representatives deem advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered. The Firm Shares will also be
offered to investors falling within the categories of investors defined in the 24th resolution of the Company’s general shareholders’ meeting held on June 27, 2023
outside the United States (i) in France and other member states of the European Union to “qualified investors” within the meaning of Article 2(e) of the Regulation (EU) 2017/1129 as may be amended from time to time (the “Prospectus Regulation”)
and (ii) outside of the European Union, pursuant to the applicable private placement exemptions in any such jurisdiction (the “European Offering”).
The Company has prepared and filed with the Securities and Exchange
Commission (the “Commission”) a shelf registration statement on Form F-3 (File No. 333-262545) with respect to the Offered Securities, including a base prospectus (the “Base Prospectus”) to be used in connection with the public offering
and sale of the Offered Securities. Such registration statement, as amended, including all documents incorporated by reference therein and the financial statements, exhibits and schedules thereto or incorporated by reference therein, in the form in
which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the “Securities Act”), including all documents incorporated or deemed to be incorporated by reference
therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or 430B under the Securities Act, is called the “Registration Statement.” Any registration statement filed by the Company pursuant to
Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called the “Rule 462(b) Registration Statement,” and from and after the date and time of filing of any such Rule 462(b) Registration
Statement the term “Registration Statement” shall include the Rule 462(b) Registration Statement. The Company and the Depositary have prepared and filed with the Commission a registration statement on Form F-6, as amended (File No. 333-250880)
relating to the Offered ADSs. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act, including all documents incorporated or
deemed to be incorporated by reference therein, is called the “F-6 Registration Statement.” The preliminary prospectus supplement dated November 2, 2023 describing the Offered Securities and the offering thereof (the “Preliminary Prospectus
Supplement”), together with the Base Prospectus, is called the “Preliminary Prospectus,” and the Preliminary Prospectus and any other prospectus supplement to the Base Prospectus in preliminary form that describes the Offered Securities
and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a “preliminary prospectus.” As used herein, the term “Prospectus” shall mean the final
prospectus supplement to the Base Prospectus that describes the Offered Securities and the offering thereof (the “Final Prospectus Supplement”), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of
the Offered Securities or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act.” As used herein, “Applicable Time” is 8:30 a.m. (New York City time) on
November 2, 2023. As used herein, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, and “Time of Sale Prospectus” means the Preliminary Prospectus, as amended or supplemented immediately prior to
the Applicable Time, together with the free writing prospectuses, if any, identified in Schedule C hereto. As used herein, “Road Show” means a “road show” (as defined in Rule 433 under the Securities Act) relating to the offering of
the Offered Securities contemplated hereby that is a “written communication” (as defined in Rule 405 under the Securities Act). As used herein, “Section 5(d) Written Communication” means each written communication (within the meaning of Rule
405 under the Securities Act) that is made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (“QIBs”)
and/or institutions that are accredited investors (“IAIs”), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered
Securities; “Section 5(d) Oral Communication” means each oral communication, if any, made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or
one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Securities; “Marketing Materials” means any materials or information provided to investors by, or with the approval of, the Company in
connection with the marketing of the offering of the Offered Securities, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and “Permitted Section 5(d) Communication” means
the Section 5(d) Written Communication(s) and Marketing Materials listed on Schedule B attached hereto.
The Company has, for the purpose of listing the Firm Shares and the
Underlying Shares on the regulated market of Euronext Paris (“Euronext”), prepared and filed with the French Financial Markets Authority (Autorité des marchés financiers) (the “AMF”), an English-language listing prospectus
consisting of (i) the universal registration document (Document d’Enregistrement Universel) filed with the AMF under number D. 23-0332 on April 24, 2023 (the “Universal Registration Document”), (ii) a first amendment to the Universal
Registration Document filed with the AMF under number D. 23-0332-A01 on November 1, 2023 (the “First Amendment”), (iv) a second amendment to the Universal Registration Document filed with the AMF under number D. 23-0332-A02 on or around
November 2, 2023 (the “Second Amendment”), (v) a securities note (Note d’opération) (the “Note d’Opération”) and (vi) a summary of such listing prospectus (included in the Note d’Opération), including the documents incorporated
by reference therein (collectively, the “French Listing Prospectus”), which is expected to receive the approval (approbation) of the AMF on or around November 2, 2023.
All references in this Agreement to the French Listing Prospectus shall
be deemed to refer collectively to (i) the Universal Registration Document and the First Amendment when such reference is made as of a date or for a period at which or during which the Second Amendment and the Note d’Opération have not yet
been filed with or approved by the AMF and (ii) after such approval has been received, to the Universal Registration Document, the First Amendment, the Second Amendment, the Note d’Opération and the summary of the French Listing Prospectus
(included in the Note d’Opération), taken together.
The Company has also published (i) a launch press release on November
1, 2023 announcing the launch of the offering of the Offered Securities (the “Launch Press Release”), and (ii) a pricing press release on November 2, 2023 (November 2, 2023, New York City time) in French and in English (the “Pricing Press
Release” and together with the Launch Press Release, the “Offering Press Releases”). The French Listing Prospectus and the Offering Press Releases are referred to together as, the “Information Documents” and individually an “Information
Document”).
“Greenshoe Press Release” means the press release to be issued by
the Company announcing the results of the offering if the overallotment option is exercised.
All references in this Agreement to the Registration Statement, the F-6
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein, including such documents filed or
furnished under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”) identified therein as being so incorporated by reference. All references in this Agreement
to financial statements and schedules and other information which are “contained,” “included” or “stated” in, or “part of” the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the
Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by
reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this
Agreement to (i) the Registration Statement, the F-6 Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing
prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (“EDGAR”) and (ii) the Prospectus shall be deemed to include any “electronic Prospectus” provided for
use in connection with the offering of the Offered Securities as contemplated by Section 3(o) of this Agreement.
The parties acknowledge that, concomitantly with the U.S. Offering and
the European Offering and subject to the Securities Purchase Agreement, dated July 7, 2023 between the Company and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), the Company shall issue up to 4,664,179 Ordinary Shares in the
form of ADSs to JJDC in accordance with Article L. 225-138 of the French Commercial Code and pursuant to the 25th and 29th resolutions of the Company’s combined general shareholders’ meeting held on June 27, 2023 (the “Strategic Offering”). No representations and warranties are given to the Underwriters with respect
to the Strategic Offering.
The Company hereby confirms its agreement with the Underwriters as follows:
Section 1. Representations and Warranties of the
Company. The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of the Option Closing Date (as defined in Section 2), if any, as
follows:
(a) Compliance with Registration Requirements.
The Registration Statement and the F-6 Registration Statement have each become effective under the Securities Act. The Company has complied, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental
information, if any. No stop order suspending the effectiveness of the Registration Statement or the F-6 Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company,
are contemplated or threatened by the Commission. At the time the Company’s Annual Report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”) was filed with the Commission, or, if later, at the time the Registration
Statement was originally filed with the Commission, the Company met the then-applicable requirements for use of Form F-3 under the Securities Act. The Company is a “foreign private issuer” within the meaning of Rule 405 under the Securities Act. The
Company meets the requirements for use of Form F-3 under the Securities Act specified in FINRA Conduct Rule 5110(B)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange
Act. In connection with the filing of the Universal Registration Document, the Company has complied, to the AMF’s satisfaction, with all requests of the AMF for additional or supplemental information, if any and the Company’s auditors have submitted
a letter of completion of work (lettre de fin de travaux) that showed no reservation, observation or warning. No order suspending the effectiveness of the Universal Registration Document has been issued by the AMF, nor has, to the Company’s
knowledge, any challenge to the filing with the AMF or the use of the Universal Registration Document been filed with any court. No order suspending the effectiveness of the French Listing Prospectus has been issued by the AMF.
(b) Disclosure. Each preliminary prospectus and
the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to the copy thereof
delivered to the Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the Registration Statement and any post-effective amendment thereto and the F-6 Registration Statement and any post-effective amendment
thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading. The Information Documents, as of their respective dates, taken together, are true, complete and accurate in all material respects. The Information Documents, taken together,
contain and will contain the necessary information which is material to an investor for making an informed assessment of the assets and liabilities, profit and losses, financial position, and prospects of the Company and on the rights attached to the
Ordinary Shares. The Information Documents conformed, conform and will conform, as appropriate, with the requirements set forth by applicable laws, including AMF regulations and the Prospectus Regulation. As of the Applicable Time, the Time of Sale
Prospectus (including any preliminary prospectus wrapper) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Information Documents do not, and, as amended or supplemented, if applicable, will not, at the First Closing Date (as defined in Section 2) and the Option Closing Date (as defined in Section 2), contain any untrue statement of a
material fact, or taken together, omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper), as of its date,
did not, and at the First Closing Date and at the Option Closing Date, if any, the Prospectus (including any Prospectus wrapper), will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The information contained in the French Listing Prospectus conforms and will conform in all material respects to the information contained in the
Registration Statement, the Time of Sale Prospectus and the Prospectus except for information included in the French Listing Prospectus and not required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus, or
information included in the Registration Statement, the Time of Sale Prospectus or the Prospectus but not required to be included in the French Listing Prospectus, in each case which is not material to the Company. The representations and warranties
set forth in the seven immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, the F-6 Registration Statement or any post-effective amendment thereto, or the
Prospectus, the Time of Sale Prospectus or the French Listing Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by
the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section 9(b) below. All notices, statements, opinions, estimates, statements of intent, projections
made by the Company in the Information Documents have been prepared in good faith and on reasonable grounds. There are no contracts or other documents required to be described in the Time of Sale Prospectus, the Prospectus or the Information
Documents or to be filed as an exhibit to the Registration Statement or the F-6 Registration Statement which have not been described or filed as required.
(c) Free Writing Prospectuses; Road Show. As of
the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an “ineligible issuer” in connection with the offering of the Offered Securities pursuant to Rules 164, 405 and 433
under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.
Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent times
through the completion of the public offer and sale of the Offered Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the
Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time. Except for the free writing prospectuses, if any, identified in Schedule B, and electronic road shows, if any, furnished to you
before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus,
did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(d) Distribution of Offering Material By the Company.
Prior to the later of (i) the expiration or termination of the option granted to the several Underwriters in Section 2, and (ii) the completion of the Underwriters’ distribution of the Offered Securities, the Company has not distributed and will not
distribute any offering material in connection with the offering and sale of the Offered Securities other than the Registration Statement, the F-6 Registration Statement, the Time of Sale Prospectus, the Prospectus, the Information Documents, the
Greenshoe Press Release or any free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on Schedule B hereto, any Permitted Section 5(d) Communications and any Road Show
furnished to you before first use.
(e) The Underwriting Agreement. This Agreement
has been duly authorized, executed and delivered by the Company.
(f) Authorization of the Offered Securities. The
Offered Securities, when issued and delivered against payment therefor pursuant to this Agreement, and upon delivery of a depositary certificate (certificat du dépositaire) in accordance with Articles L. 225-146 and L.225-138 of the French
Commercial Code and the 24th, 26th and 29th resolutions of the Company’s combined general shareholders’ meeting held on June 27, 2023, will be duly authorized, validly issued, fully paid and nonassessable, and will conform in all material
respects to the descriptions thereof in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the Information Documents and the Greenshoe Press Release, as applicable; and the issuance and sale of the Offered Securities is not
subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Securities which have not been duly excluded, waived or satisfied. The Underlying Shares may be freely deposited by the Company
with the Depositary or its nominee against issuance of ADRs evidencing the Offered ADSs, as contemplated by the Deposit Agreement. Upon the sale and delivery to the Underwriters of the Offered Securities, and payment therefor, the Underwriters will
acquire good, marketable and valid title to such Offered Securities, free and clear of all pledges, liens, security interests, charges, claims or encumbrances and will be freely transferable and there are no restrictions on subsequent transfers of
the Offered Securities under the applicable laws of France or the United States, except as described in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the Information Documents.
(g) No Applicable Registration or Other Similar
Rights. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or F-6 Registration Statement or included in the offering contemplated by this
Agreement.
(h) No Material Adverse Change. Except as
otherwise disclosed in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the Information Documents, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale
Prospectus, the Prospectus and the Information Documents: (i) there has been no material adverse change, or any development that would reasonably be expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in
the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the
ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”); (ii) the Company and its subsidiaries,
considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other
calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and
have not entered into any material transactions (not in the ordinary course of business); and (iii) there has not been any material decrease in the share capital or any material increase in any short-term or long-term indebtedness of the Company or
its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of share capital,
or any repurchase or redemption by the Company or any of its subsidiaries of any class of share capital.
(i) The Deposit Agreement; ADSs; Ordinary Shares.
The Deposit Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery by the Depositary, constitutes a valid and legally binding obligation of the Company, enforceable in
accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors’ rights generally or by general equitable principles. Upon due
issuance by the Depositary of the ADRs evidencing the Offered ADSs against the deposit of the Underlying Shares in respect thereof in accordance with the provisions of the Deposit Agreement and payment by the Underwriters for the Offered ADSs in
accordance with this Agreement, such ADSs will be duly and validly issued and the persons in whose names such ADSs are registered will be entitled to the rights specified therein and in the Deposit Agreement. The issuance and sale of the Offered ADSs
by the Company and the deposit of the Underlying Shares with the Depositary and the issuance of the ADRs evidencing the Offered ADSs as contemplated by this Agreement and the Deposit Agreement will neither (i) cause any holder of any Ordinary Shares
or ADSs, securities convertible into or exchangeable or exercisable for Ordinary Shares or ADSs or options, warrants or other rights to purchase Ordinary Shares or ADSs or any other securities of the Company to have any right to acquire any shares of
preferred stock of the Company nor (ii) trigger any anti-dilution rights of any such holder with respect to such Underlying Shares, ADSs, securities, options, warrants or rights. The Deposit Agreement and the ADRs conform in all material respects to
each description thereof in the Time of Sale Prospectus. The Ordinary Shares conform in all material respects to the description thereof in the Information Documents. Each holder of ADSs issued pursuant to the Deposit Agreement shall be entitled,
subject to the Deposit Agreement, to seek enforcement of its rights through the Depositary or its nominee registered as a representative of the holders of the ADSs in a direct suit, action or proceeding against the Company.
(j) Independent Accountants. Ernst & Young
et Autres, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) as of and for the years ended December 31, 2022 and 2021, filed with the Commission and
incorporated by reference into the Registration Statement, the Time of Sale Prospectus, and the Prospectus is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public
Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting
firm as defined by the PCAOB whose registration, to the Company’s knowledge, has not been suspended or revoked and who, to the Company’s knowledge, has not requested such registration to be withdrawn. Ernst & Young et Autres, who have certified
the financial statements of the Company as of and for the years ended December 31, 2022 and 2021 and the interim financial statements as of June 30, 2023 and 2022 included directly or incorporated by reference in the French Listing Prospectus, and
have delivered a lettre de fin de travaux with respect to the Universal Registration Document and the First Amendment, are independent statutory auditors with respect to the Company as required by the AMF General Regulations and under the
professional rules of the “Compagnie Nationale des Commissaires aux Comptes.”
(k) Financial Statements. The financial
statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of the
dates indicated and the results of their operations, changes in shareholders’ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with International Financial Reporting Standards (“IFRS”)
as issued by the European Union and the International Accounting Standards Board (the “IASB”) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto or as otherwise
disclosed therein. The financial statements included directly or incorporated by reference in the French Listing Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of the
dates indicated and the results of their operations, changes in shareholders’ equity and cash flows for the periods specified. Such financial statements as of and for the years ended December 31, 2022 and 2021 are in accordance with IFRS within the
meaning of EC Regulation No. 1606/2002 of the European Parliament and of the council of 19 July 2002 as adopted from time to time by the European Commission in accordance with that Regulation and its interpretations promulgated by the IASB applied on
a consistent basis throughout the periods involved (except as noted therein). The interim condensed consolidated financial statements as of June 30, 2022 and 2023 included directly or incorporated by reference in the French Listing Prospectus have
been prepared in accordance with IAS 34, the standard of IFRS as adopted by the European Commission applicable to interim financial statements. No other financial statements or supporting schedules are required under applicable law to be included in
or incorporated by reference into the Registration Statement, the Time of Sale Prospectus, the Prospectus or the French Listing Prospectus. The interactive data in eXtensible Business Reporting Language included or incorporated by reference into the
Registration Statement fairly presents the information called for in all material respects and has been prepared in all material respects in accordance with the Commission’s rules and guidelines applicable thereto. The financial data set forth or
incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Prospectus Supplement Summary—Corporate Updates,” and “Capitalization” and in the French Listing Prospectus fairly
present, in all material respects, the information set forth therein on a basis consistent with that of the audited financial statements contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the
Prospectus and the French Listing Prospectus. All disclosures contained or incorporated by reference in the Registration Statement, any preliminary prospectus, the Prospectus and any free writing prospectus that constitute non-GAAP financial measures
(as defined by the rules and regulations under the Securities Act and the Exchange Act) comply in all material respects with Item 10 of Regulation S-K under the Securities Act, as applicable. To the Company’s knowledge, no person who has been
suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited,
the financial statements or other financial data filed with the Commission and included in, or incorporated by reference into, the Registration Statement, the Time of Sale Prospectus and the Prospectus.
(l) Company’s Accounting System. The Company and
each of its subsidiaries make and keep accurate books and records and maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or
specific authorization; (ii) transactions are recorded as necessary to permit preparation of the Company’s financial statements in conformity with IFRS as issued by IASB and to maintain accountability for assets; (iii) access to assets is permitted
only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the
interactive data in eXtensible Business Reporting Language included or incorporated by reference into the Registration Statement, the Time of Sale Prospectus, and the Prospectus fairly presents the information called for in all material respects and
is prepared in all material respects in accordance with the Commission’s rules and guidelines applicable thereto.
(m) Disclosure Controls and Procedures; Deficiencies
in or Changes to Internal Control Over Financial Reporting. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that
information relating to the Company, including its consolidated subsidiaries, required to be disclosed by the Company in reports that it files under the Exchange Act, is made known to the Company’s principal executive officer and its principal
financial officer by others within those entities, as appropriate to allow timely decisions regarding required disclosure, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared, (ii) have
been evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal year end, and (iii) are effective in all material respects to perform the functions for which they were established. Except as otherwise
disclosed in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus, since the end of the Company’s most recent audited fiscal year, there have been no material weaknesses in the Company’s internal
control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
Company’s internal control over financial reporting.
(n) Incorporation and Power of the Company. The
Company is duly constituted and is validly existing as a société anonyme under the laws of France and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the Time of Sale Prospectus, the Prospectus and the Universal Registration Document and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in
good standing (where such concept exists) in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in
good standing outside of France would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), earnings, business, properties, operations, assets or liabilities of the
Company and its subsidiaries, considered as one entity or on the performance by the Company of its obligations under this Agreement and the Deposit Agreement (a “Material Adverse Effect”). No proceeding of mandat ad hoc, conciliation,
sauvegarde (including sauvegarde accélérée), redressement judiciaire or liquidation judiciaire is existing with respect to the Company and the Company is not insolvent. The by-laws (statuts) of the Company comply with the
requirements of applicable French law and are in full force and effect in all material respects. Each member of the corporate bodies of the Company has been duly elected or appointed in such capacity and exercises his or her functions in accordance
with applicable laws and regulations and the Company’s by-laws and internal regulations.
(o) Subsidiaries. Each of the Company’s
“subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as
applicable, in good standing (where such concept exists) under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business
as described in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus. Each of the Company’s subsidiaries is duly qualified as a corporation, partnership or limited liability company, as applicable,
to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good
standing would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. All of the issued and outstanding share capital or other equity or ownership interests of each of the Company’s subsidiaries have been
duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the
outstanding share capital or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. No proceeding of mandat ad hoc, conciliation, sauvegarde (including sauvegarde
accélérée), redressement judiciaire or liquidation judiciaire is existing with respect to any of the Company’s subsidiaries and each of the Company’s subsidiaries is not insolvent. The constitutive or organizational documents of each of the
subsidiaries comply with the requirements of applicable laws of its jurisdiction or incorporation or organization and are in full force and effect, except as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in or included as an exhibit to the Registration Statement and the French Listing Prospectus.
(p) Capitalization and Other Share Capital Matters.
The authorized, issued and outstanding share capital of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Capitalization” and in the Information Documents (in each case, other
than for subsequent issuances, if any, pursuant to employee or non-employee director or management benefit plans, stock-option and free share plans or upon the exercise of outstanding founders’ warrants (BSPCE), stock options (OSA) and warrants
(BSA), or the vesting of free shares in each case described in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus). The share capital of the Company, including the Offered Securities, conforms in
all material respects to each description thereof contained in the Time of Sale Prospectus and the Information Documents as of their respective dates. All of the issued and outstanding Ordinary Shares have been duly authorized and validly issued, are
fully paid and nonassessable, freely negotiable and have been issued in compliance with French law and, to the extent applicable, all United States federal, state and local securities laws. None of the outstanding Ordinary Shares was issued in
violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company that have not been duly excluded, waived or satisfied. There are no authorized or outstanding options,
warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any share capital of the Company or any of its subsidiaries other than those described
in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus. The descriptions of the Company’s (i) free shares, stock option, stock bonus and other stock plans or arrangements, and the options or other
rights granted thereunder, and (ii) founders’ warrants (BSPCE) and warrants (BSA), and the rights set forth in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus accurately and fairly present the
information required to be shown with respect to such plans, arrangements, options, warrants and rights. The ADRs evidencing the Offered ADSs are in due and proper form. With respect to the outstanding founder’s share warrants (BSPCE), stock options,
share warrants (BSA) and free shares (actions gratuites), in each case referred to in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus, (i) each grant was duly authorized no later than
the date on which such grant was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the management board and supervisory board of the Company and any required shareholder approval by the necessary
number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii) each such grant was made in accordance with the terms of the relevant plan adopted by the Company,
as the case may be amended, and all other applicable laws and regulatory rules or requirements, including the rules of the AMF and Euronext, and (iii) each such grant was properly accounted for in accordance with IFRS in the financial statements
(including the related notes) of the Company.
(q) Working Capital. The cash flow and working
capital projections on which the Company has based its working capital statements which will be contained in the Section 3.1 of the Note d’Opération and in Section 4.3 of the summary of the French Listing Prospectus and in the Offering Press
Releases have been made on reasonable grounds in good faith, after due and careful enquiry and take into account all material matters of which the Company is aware concerning the Company and its subsidiaries. All assumptions on which such working
capital statement is based are reasonable and, so far as the Company is aware, there are no other material assumptions which should reasonably be taken into account in the preparation of such working capital statement.
(r) Stock Exchange Listing. The Company’s ADSs
are registered pursuant to Section 12(b) of the Exchange Act and are listed on The Nasdaq Global Market (“Nasdaq”), and the Company has taken no action designed to, or likely to have the effective of, terminating the registration of the
Company’s ADSs under the Exchange Act or delisting the ADSs from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company’s knowledge, it is in
compliance with all applicable listing requirements of Nasdaq. The Company will use commercially reasonable efforts to maintain the listing of the Ordinary Shares (including the Underlying Shares) on Euronext and will comply with all laws and
regulations applying to it due to the listing of the Firm Shares and the Underlying Shares on Euronext.
(s) Non-Contravention of Existing Instruments; No
Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is in violation of its articles of association or by-laws, partnership agreement or operating agreement or similar organizational documents, as
applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including,
without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any
of them may be bound, or to which any of their respective properties or assets are subject (each, an “Existing Instrument”), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby, by the Deposit Agreement and by the Registration Statement, the F-6 Registration Statement, the Time of Sale
Prospectus, the Prospectus, the French Listing Prospectus and the Offering Press Releases and the issuance and sale of the Offered Securities (including the use of proceeds from the sale of the Offered Securities as described in the Registration
Statement, the Time of Sale Prospectus, the Prospectus under the caption “Use of Proceeds,” the French Listing Prospectus under the caption “Purpose of the issuance and use of proceeds” and in the Offering Press Releases) (i) have been duly
authorized by all necessary corporate action and will not result in any violation of the provisions of the articles of association or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the
Company or any subsidiary, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree
applicable to the Company or any of its subsidiaries, except for such violations, conflicts, breaches, Defaults, Debt Repayment Triggering Event, lien, charge or encumbrance specified in clauses (ii) and (iii) above as would not, individually or in
the aggregate, reasonably be expected to result in a Material Adverse Effect. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for
the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, by the Deposit Agreement and by the Registration Statement, the F-6 Registration Statement, the Time of Sale Prospectus and
the Prospectus, except for the approval by the AMF of the French Listing Prospectus and the publication by Euronext of notices (avis) with respect to the listing of the Firm Shares and the Underlying Shares and such as have been obtained or
made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or the Financial Industry Regulatory Authority, Inc. (“FINRA”) or Nasdaq. As used
herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such
holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.
(t) Compliance with Laws. The Company and its
subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.
(u) No Material Actions or Proceedings. There is
no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would reasonably be
expected, individually or in the aggregate, to result in a Material Adverse Effect. No labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor
of the Company, exists or, to the knowledge of the Company, is threatened or imminent, which could reasonably be expected to result in a Material Adverse Effect.
(v) Intellectual Property Rights. The Company and
its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration
Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be
conducted (collectively, “Intellectual Property”). To the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to
Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii) there is no infringement by
third parties of any Intellectual Property that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by
others: (A) challenging the Company’s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability
or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise
violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the French Listing Prospectus as under development, infringe or violate, any patent,
trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. Except as would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or
any subsidiary, and all such agreements are in full force and effect. The product candidates described in the Registration Statement, the Time of Sale Prospectus, the Prospectus and the French Listing Prospectus as under development by the Company or
any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.
(w) All Necessary Permits, etc. The Company and
its subsidiaries possess such valid and current certificates, authorizations or permits required by French, United States (state or federal) or other foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted
and as described in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the French Listing Prospectus (“Permits”), except where failure to so possess would not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the
Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such Permit.
(x) Title to Properties. The Company and its
subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 1 (k) above (or elsewhere in the Registration Statement, the Time of Sale
Prospectus, the Prospectus or the French Listing Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. The real property, improvements, equipment and personal property material to its business held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases,
with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.
(y) Tax Law Compliance. The Company and each of
its subsidiaries have timely filed with the appropriate governmental authority all United States federal, state, local, and non-United States tax returns required to be filed through the date hereof, or have properly requested extensions thereof,
such tax returns are true, correct and complete in all respects, and the Company and each of its subsidiaries have timely paid all taxes required to be paid by any of them (whether or not shown on a tax return) through the date hereof including any
related or similar assessment, interest, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings or except where the failure to file a tax return or the failure to pay any tax would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company or its subsidiaries is under audit by any governmental authorities, and none of them has received written notice of any pending or
threatened audit other than with respect to routine tax audits which the Company does not reasonably believe would have a Material Adverse Effect. The Company has made adequate charges, accruals and reserves in the applicable financial statements
referred to in Section 1(k) above in respect of all United States federal, state, local, and non-United States taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined. Except as
described in the Registration Statement or the Prospectus, no transaction, documentary, stamp, capital or other issuance, registration, transaction, transfer or withholding tax or duty (including, for the avoidance of doubt, financial transaction tax
as set out in Article 235 ter ZD of the Code général des impôts) is payable in France by or on behalf of the Underwriters to any taxing authority in connection with (i) the issuance, sale and delivery of the Offered Securities by the Company,
the issuance of the ADSs by the Depositary, and the delivery of the Offered Securities (other than the ADSs) to or for the account of the Underwriters; (ii) the purchase from the Company, and the initial sale, transfer and delivery by the
Underwriters of the Offered Securities to purchasers thereof; (iii) the deposit of the Ordinary Shares with the Depositary and the issuance and delivery by the Depositary of the ADRs evidencing the ADSs; or (iv) the execution, delivery and
consummation of this Agreement or the Deposit Agreement or any other document to be furnished hereunder.
(z) Insurance. Each of the Company and its
subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but
not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product
liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable
coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has
been denied any insurance coverage which it has sought or for which it has applied.
(aa) Compliance with Environmental Laws. Except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i) neither the Company nor any of its subsidiaries is in violation of any French, U.S. (federal, state or local) or other foreign statute, law,
rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human
health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of
chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company and its subsidiaries have all permits, authorizations, and approvals required under any applicable Environmental Law and are each in compliance
with their requirements; (iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or
proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) to the Company’s knowledge, there are no events or circumstances existing as of the date hereof that might reasonably be expected to form the basis
of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.
(bb) ERISA Compliance. The Company and its
subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by
the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any member of any group of
organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member. Except
as would not be reasonably expected to result in a Material Adverse Effect, no “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the
Company, its subsidiaries or any of their ERISA Affiliates. Except as would not be reasonably expected to result in a Material Adverse Effect, no “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA
Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Except as would not be reasonably expected to result in a Material Adverse Effect, none of the Company, its
subsidiaries or any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or
4980B of the Internal Revenue Code of 1986, as amended (the “Code”). Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a)
of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.
(cc) Company Not an “Investment Company”; Not a
“Passive Foreign Investment Company”. The Company is not, and will not be, either after receipt of payment for the Offered Securities or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, and in the French Listing Prospectus under the caption “Purpose of the issuance and use of proceeds” and the Offering Press Releases, required to register as an “investment company”
under the Investment Company Act of 1940, as amended (the “Investment Company Act”). For the taxable year ended December 31, 2022, the Company does not believe that it was a “passive foreign investment company” (“PFIC”) as such term is
defined in Section 1297 of the Code, and it is not yet known whether the Company will be a PFIC for the taxable year that includes the offering and sale of the Offered Securities.
(dd) No Price Stabilization or Manipulation; Compliance
with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly (without giving effect to the activities by the Underwriters), any action designed to or that would reasonably be expected to cause or result
in any unlawful stabilization or manipulation of the price of the Offered Securities or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Offered Securities,
whether to facilitate the sale or resale of the Offered Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M. Neither the Company, nor any of its subsidiaries, has taken, directly or indirectly, any
action designed to cause or to result in, or that has constituted or that might reasonably be expected to cause or result in, the stabilization of the Offered Securities in violation of applicable European Union or French laws or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Offered Securities. The Company has not taken or omitted to take any action nor will take any action or omit to take any action which may result in the loss by any of the
Underwriters of the ability to rely on any stabilization safe harbor provided under the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard
to regulatory technical standards for the conditions applicable to buy-back programs and stabilization measures. The Company authorizes Jefferies to make adequate public disclosure of information, and to act as the central point responsible for
handling any request from a competent authority, in each case as required by Article 6(5) of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016 as amended, with regard to regulatory technical standards for conditions applicable to
buy-back programs and stabilization measures.
(ee) No Market Abuse. The Company has complied in
all material respects with the applicable provisions of EU Regulation No 596/2014 of April 16, 2014 on market abuse, as amended, delegated EU regulations adopted thereunder and the equivalent French laws and regulations (the “Market Abuse Rules”)
and has taken adequate measures and has adequate procedures in place in order to ensure such compliance. Neither the allotment of the Offered Securities nor the sale of the Offered Securities and the consummation of the transactions contemplated by
this Agreement will cause or result in the violation of any material provision of the Market Abuse Rules, and no Company’s executive directors, board members and supervisory board members and to the knowledge of
the Company, no officer, agent, or other person acting on behalf of the Company (except for the Underwriters, in respect of which the Company makes no representation) has done any act or engaged in any course of conduct constituting such
violation.
(ff) Related-Party Transactions. There are no
business relationships or related-party transactions, including conventions réglementées under Article L. 225-86 et seq. of the French Commercial Code, involving the Company or any of its subsidiaries or any other person required to
be described in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the French Listing Prospectus that have not been described as required.
(gg) FINRA Matters. All of the information provided
to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors, in connection with the offering of the Offered Securities is, to the Company’s knowledge, true, complete, correct and compliant with
FINRA’s rules in all material respects and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects.
(hh) Parties to Lock-Up Agreements. The Company has
furnished to the Representatives a letter agreement in the form attached hereto as Exhibit E (the “Lock-up Agreement”) from each of the persons listed on Exhibit F. Such Exhibit F lists under an appropriate caption the
executive board members and supervisory board members of the Company. If any additional persons shall become executive board members or supervisory board members of the Company prior to the end of the Company Lock-up Period (as defined below), the
Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.
(ii) Statistical and Market-Related Data. All
statistical, demographic and market-related data included in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents are based on or derived from sources that the Company believes, after reasonable
inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written consent to the use of such data from such sources.
(jj) No Unlawful Contributions or Other Payments.
Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign
office in violation of any law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents.
(kk) Anti-Corruption and Anti-Bribery Laws. Neither
the Company nor any of its subsidiaries nor any, to the knowledge of the Company, any board member, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for,
or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer,
promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political
party, party official or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, Articles 432-11 et seq., 433-1 and
433-2, 433-22 to 433-25, 435-1 et seq. and 445-1 et seq. of the French Criminal Code, or any other applicable anti-bribery or anti-corruption law of the European Union or any other jurisdiction in which the Company conducts its
business; or (iv) made, offered, authorized or requested any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s
affiliates have conducted their respective businesses in compliance with the FCPA, and have instituted and maintain, policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
(ll) Money Laundering Laws. The operations of the
Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency, including but not limited to, the Cellule
française de lutte contre le blanchiment de capitaux et le financement du terrorisme (TRACFIN) and the Office central pour la répression de la grande délinquance financière (OCRGDF) (collectively, the “Money Laundering Laws”)
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the
Company, threatened.
(mm) Sanctions.
Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, after due inquiry, any board member, officer, agent, employee, affiliate or other person acting on behalf of the Company (except for the Underwriters, in respect
of which the Company makes no representation) or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the
U.S. Department of State, the United Nations Security Council, the European Union, His Majesty’s Treasury of the United Kingdom, any French government agency or other relevant sanctions authority (collectively, “Sanctions”); nor is the
Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Russia, Belarus, Crimea, Donetsk People’s Republic and Luhansk People’s
Republic regions of Ukraine, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint
venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other
manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries
have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.
(nn) Brokers. Except pursuant to this Agreement,
there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.
(oo) Submission to Jurisdiction. The Company has the
power to submit, and pursuant to Section 18 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each United States federal court and New York state court located in the Borough of Manhattan,
in the City of New York, New York, U.S.A. (each, a “New York Court”), and the Company has the power to designate, appoint and authorize, and pursuant to Section 18 of this Agreement, has legally, validly, effectively and irrevocably
designated, appointed and authorized an agent for service of process in any action arising out of or relating to this Agreement or the Offered Securities in any New York Court, and service of process effected on such authorized agent will be
effective to confer valid personal jurisdiction over the Company as provided in Section 18 hereof.
(pp) No Rights of Immunity. Except as provided by
laws or statutes generally applicable to transactions of the type described in this Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of immunity under French, New York or United States law, from
any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding, from set-off or counterclaim, from the jurisdiction of any French, New York or United States federal court, from service of process,
attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court, with respect
to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement or the Deposit Agreement. To the extent that the Company or any of its respective properties, assets or revenues may have or may
hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time be commenced, the Company waives or will waive such right to the extent permitted by law and has consented to such relief and enforcement
as provided in Section 18 of this Agreement.
(qq) Enforceability of Judgments. Any final judgment
for a fixed or readily calculable sum of money rendered by a New York Court in respect of any suit, action or proceeding against the Company based upon this Agreement or the Deposit Agreement would be recognized and enforced in France, without a
review of the substantive matters thereby adjudicated, through an action for exequatur brought before the competent French court (subject to appeal against the exequatur order itself, again without a review of the substantive matters adjudicated by
the relevant final judgment, and subject to further recourse before the French Supreme Court, again without a review of the substantive matters adjudicated by the relevant final judgment), provided that such French court is provided with a
French-language version of this Agreement, and/or the Deposit Agreement, or relevant excerpts thereof to the extent required and both the original and a translation into French (by a sworn translator) of the relevant final judgment and other relevant
documents and determines that the requirements developed by case law for the enforcement of foreign judgments are satisfied, in particular that:
(i) such final judgment was rendered by a court having
jurisdiction over the matter, as the dispute is clearly connected to the jurisdiction of such court (i.e., there was no international forum-shopping), the choice of the New York Court was not fraudulent and the French courts did not have exclusive
jurisdiction over the matter;
(ii) such final judgment does not contravene French
international public policy rules, both pertaining to the merits and to the procedure of the case, including fair trial rights; and
(iii) such final judgment is not tainted with fraud under
French law (i.e., the parties did not submit the dispute to a foreign court in order to maliciously avoid the application of French law) and does not conflict with a French judgment or a foreign judgment having the same subject-matter that has become
effective in France.
(rr) Forward-Looking Statements. Each financial
or operational projection or other “forward-looking statement” (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the
Information Documents (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by
meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the
Company that it was false or misleading.
(ss) Compliance with The Sarbanes-Oxley Act and Nasdaq
Governance Requirements. The Company is in compliance in all material respects with all applicable (i) provisions of the Sarbanes-Oxley Act of 2002 and rules and regulations promulgated thereunder or implementing the provisions thereof
(collectively, the “Sarbanes-Oxley Act”) that are then in effect and with which the Company is required to comply, and is or will be taking steps to ensure that it will be in compliance in all material respects with other provisions of the
Sarbanes-Oxley Act not currently in effect, upon the effectiveness of such provisions and their becoming applicable to the Company and (ii) corporate governance requirements under Nasdaq regulations and, in each case, has no reason to believe that it
will not be able to comply with any of such provisions. There is and has been no failure on the part of the Company or any of its directors or officers, in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act,
including without limitation, Sections 302 and 906 related to certifications. The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the
Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.
(tt) Cybersecurity. The Company and its
subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects
as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear, to the Company’s knowledge, of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its subsidiaries have implemented and maintained controls, policies, procedures, and safeguards consistent with industry standards and practices for similarly-situated companies to maintain and protect their material
confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name,
street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information
which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by the European Union General Data Protection Regulation (EU 2016/679) (“GDPR”); and (iv) any
information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”).
Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied
without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws
or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to
the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.
(uu) Compliance with Data Privacy Laws. The Company
and its subsidiaries are, to the extent applicable to the Company’s operations, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its
subsidiaries have defined a compliance program to be implemented in order to comply with GDPR (collectively, the “Privacy Laws”). The Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its
subsidiaries have at all times made all material disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in violation of
any applicable laws and regulatory rules or requirements in any material respect. Neither the Company nor any of its subsidiaries: (i) has received notice alleging any actual or potential liability under or relating to, or actual or potential
violation of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement
that imposes any material obligation or liability under any Privacy Law.
(vv) Emerging Growth Company Status. From the time
of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof,
the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
(ww) Communications. The Company (i) has not alone
engaged in communications with potential investors in reliance on Section 5(d) of the Securities Act other than Permitted Section 5(d) Communications with the consent of the Representatives with entities that are QIBs or IAIs and (ii) has not
authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section 5(d) Oral Communications and
Section 5(d) Written Communications; as of the Applicable Time, each Permitted Section 5(d) Communication, when considered together with the Time of Sale Prospectus and the Information Documents, did not, as of the Applicable Time, include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted Section 5(d) Communication, if any, does
not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus, the Prospectus and the Information Documents; provided that the Company makes no representation or warranty with respect to
any statements or omissions made in each such Permitted Section 5(d) Communication in reliance upon and in conformity with written information furnished to the Company in writing by the Representatives expressly for use in such Permitted Section 5(d)
Communication, it being understood and agreed that the only such information furnished by the Representatives consists of the information described as such in Section 9(b) hereof; and (iii) the Company has filed publicly on EDGAR, at least 48 hours
prior to the effectiveness of the Registration Statement in accordance with Rule 461 under the Securities Act, any confidentially submitted registration statement relating to the offer and sale of the Offered Securities.
(xx) Clinical Data and Regulatory Compliance. The
preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information
Documents were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies, as amended from time to time; each description of the results of such
studies is accurate and complete in all material respects and fairly presents in all material respects the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies, other than as may be addressed in
the Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents, the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the
Time of Sale Prospectus, the Prospectus or the Information Documents when viewed in the context in which such results are described and the state of development; the Company and its subsidiaries have made all such filings and obtained all such
approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical device regulatory agency (including the Agence Nationale de
Sécurité du Médicament et des Produits de Santé (“ANSM”)), or Institutional Review Board (collectively, the “Regulatory Agencies”) to conduct their respective businesses as currently conducted and as described in the Registration
Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents; except as disclosed in the Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents, neither the Company nor any of its
subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification before proceeding of any clinical trials that are described or referred to in the Registration Statement, the
Time of Sale Prospectus, the Prospectus or the Information Documents; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the
Regulatory Agencies.
(yy) Compliance
with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance with all Health Care Laws applicable to the Company and its subsidiaries, except as would reasonably be expected individually or in the
aggregate to have a Material Adverse Effect. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), Public Health
Service Act (42 U.S.C. §§ 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C.
Section 1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), U.S. Physician Payments Sunshine Act (42 U.S.C. Section 1320a-7h), all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C.
Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion law (42 U.S.C. Section 1320-7), the
statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; (iii) the Standards for Privacy of Individually Identifiable Health Information, 45
C.F.R. parts 160 and 164 (subparts A and E) (the “Privacy Rule”), the Security Standards, 45 C.F.R. parts 160 and 164 (subparts A and C), the Breach Notification Rule, 45 C.F.R. part 164 (subpart D), and the Standards for Electronic Transactions and Code Sets, 45 C.F.R. part 162, promulgated under HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section 17921 et seq.), and the regulations promulgated thereunder and any state or non-U.S. counterpart thereof or other law or regulation the purpose of which is to protect the privacy of individuals or prescribers; (iv) the Patient Protection
and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, and the regulations promulgated thereunder; (v) the U.S. Controlled Substances Act (21 U.S.C. Section 801 et seq.); (vi) licensure, quality,
safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vii) all other local, state, federal, national, supranational and foreign laws, applicable to the Company or its subsidiaries,
except as would reasonably be expected individually or in the aggregate to have a Material Adverse Effect. Neither the Company nor its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws that has not been
resolved nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. Except as would not reasonably be expected individually or in the aggregate to have
a Material Adverse Effect, (i) the Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by
any Health Care Laws, and (ii) all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, accurate and not misleading on the date filed in all material respects (or were
materially corrected or supplemented by a subsequent submission). Neither the Company nor its subsidiaries is a party to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders,
or similar agreements with or imposed by any governmental or regulatory authority with respect to Health Care Laws. Additionally, neither the Company, its subsidiaries nor, to the knowledge of the Company, any of the Company’s or its subsidiaries’
respective employees, officers or directors has been excluded, suspended or debarred from participation in any U.S. federal or state health care program or human clinical research or is subject to a governmental inquiry, investigation, proceeding,
or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.
(zz) No Contract Terminations. Neither the Company
nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus, the Prospectus, the Information Documents
or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement or the F-6 Registration Statement, or any document incorporated by reference therein, and no such termination or non-renewal has
been threatened by the Company or any of its subsidiaries or, to the Company’s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof, except, in each
case, as described or contemplated by the Registration Statement, the F-6 Registration Statement, the Time of Sale Prospectus, the Prospectus or the Information Documents.
(aaa) Dividend Restrictions. No subsidiary of the
Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary’s equity securities or from repaying to the Company or any other subsidiary of
the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.
Any certificate signed by any officer of the Company or any of its
subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Securities shall be deemed a representation and warranty by the Company to each Underwriter as
to the matters covered thereby.
The Company has a reasonable basis for making each of the
representations set forth in this Section 1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section 6 hereof, counsels to the Company and counsels to the Underwriters, will rely upon the
accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.
Section 2. Purchase, Sale and Delivery of the Offered Securities.
(a) The Firm Securities. Upon the terms herein
set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of 3,106,907 Firm ADSs and 2,492,223 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject
to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company up to the respective number of Firm ADSs or Firm Shares, as applicable, set forth opposite their names on Schedule A, at the
purchase price set forth in accordance with Section 2(d) below; plus any additional number of Firm Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 11 (subject, in each case, to such adjustments
among the Underwriters as the applicable Representatives in their sole discretion shall make to eliminate any sales or purchase of fractional Ordinary Shares or ADSs, as the case may be). It is understood that the obligations of the Underwriters
contained in this Agreement shall not constitute a performance guarantee (garantie de bonne fin) within the meaning of Article L. 225-145 of the French Commercial Code.
(b) The First Closing Date. Delivery of
certificates or book-entry positions for the Firm Securities to be purchased by the Underwriters and payment therefor shall be made at the offices of Cooley LLP, New York, NY (or such other place as may be agreed to by the Company and the
Representatives) at 3:00 a.m. New York City time, on November 6, 2023, or such other time and date not later than 10:00 a.m. New York City time on the tenth business day thereafter, as the Representatives shall designate by notice to the Company (the
time and date of such closing are called the “First Closing Date”). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but
are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section 11.
(c) The Option ADSs; Option Closing Date. In
addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby agrees to issue, at the option of the several Underwriters, up to an
aggregate of 839,869 Option ADSs at the ADS Purchase Price (as defined below) to be sold to the several Underwriters. The option granted hereunder may be exercised at any time in whole or in part upon notice by the Representatives to the Company,
which notice may be given at any time within 30 days from the date of this Agreement. Such notice shall set forth (i) the aggregate number of Option ADSs as to which the Underwriters are exercising the option and (ii) the time, date and place at
which the Option ADSs will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term “First Closing
Date” shall refer to the time and date of delivery of the Firm Securities and such Option ADSs). Such time and date of delivery, if subsequent to the First Closing Date, is called the “Option Closing Date,” shall be determined by the
Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise. If any Option ADSs are to be purchased, each relevant Underwriter agrees, severally and not jointly, to purchase that
proportion of the total number of Option ADSs then being purchased which the number of Firm ADSs or Firm Shares, as the case may be, as set forth on Schedule A opposite the name of such relevant Underwriter bears to the total number of Firm
Securities to be purchased (subject to such adjustments to eliminate fractional Ordinary Shares or ADSs, as the case may be, as the applicable Representatives may determine). The Representatives and the Company, by mutual consent, may determine that
all or a portion of the Option ADSs be delivered as Ordinary Shares, and payment therefor shall be made in U.S. Dollars or Euros, as the case may be.
(d) Payment for the Offered Securities. The Firm
Shares and the Firm ADSs (and, as the case may be, the Option ADSs) are being offered as part of a single capital increase at an identical price of $5.36 per ADS (the “ADS Purchase Price”) corresponding to €5.07 per Ordinary Share (the “Share
Purchase Price” and, together with the ADS Purchase Price, the “Offering Price”) based upon the exchange rate, as agreed between the Company and the Representatives, and exclusive of the commissions set forth in Section 2(f) below.
Payment of the Share Purchase Price or the ADS Purchase Price, as applicable, for the Offered Securities shall be made to the Company on or prior to the First Closing Date (and, as the case may be, on or prior to the Option Closing Date) (i) in Euros
with respect to the Firm Shares by wire transfer or credit of immediately available funds of an amount equal to the product of 2,492,223 Firm Shares sold in the European Offering by the Ordinary Share Purchase Price to the account or accounts
designated by the Company in writing at least two business days prior to the First Closing Date (or the Option Closing Date, as the case may be), which account shall be held at CM-CIC Securities, as transfer agent and registrar of the Company (the “Registrar”),
by the European Representative for purposes of settlement and delivery of the Firm Shares and (ii) in United States dollars with respect to the Firm ADSs (or Option ADSs, as the case may be) by wire transfer or credit of immediately available funds
of an amount equal to the product of the 3,106,907 Firm ADSs (or the Option ADSs, as the case may be) sold in the U.S. Offering by the ADS Purchase Price to the account or accounts designated by the Company in writing at least two business days prior
to the First Closing Date (or the Option Closing Date, as the case may be), which account shall be held at the Registrar, by Jefferies as Representative of the Underwriters for purposes of settlement and delivery of the Offered ADSs. No later than
10:00 a.m. Central European Time on the First Closing Date and, as the case may be, the Option Closing Date, the Registrar shall issue one depositary certificate (certificat du dépositaire) in accordance with Article L. 225-146 of the French
Commercial Code, relating to the capital increase, and, as the case may be, the additional capital increase, of the Company, and shall deliver three originals of such certificate to the Company. At least one full business day prior to the First
Closing Date, the Company shall have taken all actions and provided the Registrar with all notices, documents, corporate authorizations or other instruments necessary or required to effectuate the issuance of the certificat du dépositaire referred
herein.
(e) Delivery of the Offered Securities. On the
First Closing Date and, as the case may be, on the Option Closing Date, immediately after issuing the certificat du dépositaire, the Registrar shall: (i) send to Euroclear France, in the name and on behalf of the Company, a lettre
comptable for the creation of the Firm Shares and of the Underlying Shares corresponding to the Firm ADSs (and, as the case may be, the Option ADSs) and for credit thereof no later than on the First Closing Date (and, as the case may be, the
Option Closing Date) in a securities account opened in the name and on behalf of the Company in the books of the Registrar; (ii) transfer and credit the Firm Shares to a securities account opened in the books of the European Representative for
purposes of settlement and delivery of the Offered Securities; and (iii) transfer the Underlying Shares corresponding to the Firm ADSs (and, as the case may be, the Option ADSs) to Citibank, N.A., as custodian under the Deposit Agreement, for the
account of the Depositary against issuance of ADRs evidencing ADSs in accordance with the Deposit Agreement. Delivery of the Offered ADSs and/or the ADRs evidencing Offered ADSs shall be made through the facilities of the Depository Trust Company (“DTC”)
unless the applicable Representatives shall otherwise instruct. Prior to the First Closing Date, the Company shall have taken all actions and made all necessary filings with Euronext and Euroclear France, and with the Depositary and DTC, to
facilitate the transfer of the Firm Shares through Euroclear France and the Offered ADSs through DTC. The ADRs evidencing the Offered ADSs shall be registered in such names and denominations as the applicable Representatives shall have requested at
least one full business day prior to the First Closing Date (or the Option Closing Date, as the case may be). Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of
the Underwriters.
(f) Underwriting Commissions. As compensation
for the Underwriters’ commitments, the Company shall pay, or cause the Registrar to pay, to Jefferies, as Representative of the Underwriters for purposes of settlement and delivery of the Offered Securities, a commission equal to the product of $0.58
and the number of Firm ADSs (and/or Option ADSs, as the case may be) to be issued at the First Closing Date (or the Option Closing Date, as the case may be). The aforementioned commissions shall be deducted from the gross proceeds payable to the
Company on the First Closing Date (or the Option Closing Date, as the case may be) and shall be paid on such date by the Registrar to the Underwriters as soon as possible after issuance of the certificat du dépositaire referred to in Section
2(d) above. The Company irrevocably agrees to such transfer. The underwriting commissions payable on the First Closing Date (or the Option Closing Date, as the case may be) will be divided in the following proportions: 42.00% for Jefferies 37.00% for
Leerink and 21.00% for Guggenheim.
Section 3. Additional Covenants of the Company. The
Company further covenants and agrees with each Underwriter as follows:
(a) Delivery of Registration Statement, F-6
Registration Statement, Time of Sale Prospectus and Prospectus. The Company shall furnish to you in New York City, without charge, as promptly as practicable on the business day next succeeding the date of this Agreement and during the period
when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered
Securities, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement or the F-6 Registration Statement as you may reasonably request.
(b) Representatives’ Review of Proposed Amendments
and Supplements. During the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), the Company (i) will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement or the F-6 Registration Statement, a copy of
each such amendment or supplement and (ii) will not amend or supplement the Registration Statement or the F-6 Registration Statement (including, in each case, any amendment or supplement through incorporation of any report filed under the Exchange
Act) without the Representatives’ prior written consent, which shall not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including, in
each case, any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed
amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives’ prior written consent, which shall not be unreasonably withheld,
conditioned or delayed. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. The information contained in such amendment
or supplement shall be made available, to the extent the Representatives reasonably determine that it is required by applicable French laws after consultation with the Company, to the public in France, either through the Note d’Opération or,
after the French Listing Prospectus has been approved by the AMF, through a press release broadcasted pursuant to applicable AMF rules or, if necessary, a supplement to the French Listing Prospectus.
(c) Free Writing Prospectuses. The Company shall
furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by,
or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives’ prior written consent, which shall not be unreasonably withheld,
conditioned or delayed. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at
any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities (but in any event if
at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would
conflict with the information contained in the Registration Statement or the F-6 Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free
writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time,
not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives’ prior
written consent, which shall not be unreasonably withheld, conditioned or delayed.
(d) Filing of Underwriter Free Writing Prospectuses.
The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such
Underwriter that such Underwriter otherwise would not have been required to file thereunder.
(e) Approval to be Granted by the AMF on the French
Listing Prospectus. The Company shall take the necessary steps to obtain from the AMF an approval on the French Listing Prospectus.
(f) Delivery of a Lettre de Fin de Travaux
on each of the Second Amendment and the Note d’Opération. The Company shall take the necessary steps to obtain from Ernst & Young et Autres a lettre de fin de travaux on the Second Amendment and the Note d’Opération (a copy of each
of which will be given to the AMF pursuant to article 212-15 of the General Regulations of the AMF), that will show no reservation, observation or warning.
(g) Amendments and Supplements to Time of Sale
Prospectus. If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration
Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare,
file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or
supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so
that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement or the F-6 Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented,
will comply with applicable law. The information contained in such amendment or supplement shall be made available, to the extent the Representatives reasonably determine that it is required by applicable French laws after consultation with the
Company, to the public in France, either through the Note d’Opération or, after the French Listing Prospectus has been approved by the AMF, through a press release broadcasted pursuant to applicable AMF rules or, if necessary, a supplement
to the Note d’Opération.
(h) Certain Notifications and Required Actions.
After the date of this Agreement, the Company shall promptly advise the Representatives in writing of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission or the AMF relating to the
Registration Statement, the French Listing Prospectus or the Offering Press Releases, as the case may be, received by the Company before the later of one year from the date of this Agreement or the expiration of the period during which a prospectus
relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule); (ii) the time and date of any filing of any post-effective
amendment to the Registration Statement or the F-6 Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, the Prospectus or the French Listing Prospectus; (iii)
the time and date that any post-effective amendment to the Registration Statement or the F-6 Registration Statement becomes effective; (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or
any post-effective amendment thereto or the F-6 Registration Statement or any post-effective amendment thereto, or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or
suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Offered Securities from any securities
exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes; and (v) the issuance by the AMF of any order preventing or suspending the use of
the French Listing Prospectus or of any challenge to the filing with the AMF or the use of the French Listing Prospectus. If the Commission shall enter any such stop order or the AMF shall issue such order or if any such challenge is issued at any
time, the Company will use its best efforts to obtain the lifting of such order or to oppose such challenge at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433
and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.
(i) Amendments and Supplements to the Prospectus and
Other Securities Act Matters. If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a
purchaser, not misleading, or if in the opinion of the Representatives or counsels for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and
Section 3(c) hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended
or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives’ consent to, nor
delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under Section 3(b) or Section 3(c). The information contained in such amendment or supplement shall be made available, to the extent required
by applicable French laws, to the public in France, either through the Note d’Opération or, after the French Listing Prospectus has been approved by the AMF, through a press release broadcasted pursuant to applicable AMF rules or, if
necessary, a supplement to the French Listing Prospectus.
(j) Blue Sky Compliance. The Company shall
cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities
laws (or other foreign laws) of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered
Securities. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to
taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Securities for offering, sale or trading in any
jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal
thereof as soon as possible.
(k) Use of Proceeds. The Company shall apply the
net proceeds from the sale of the Offered Securities sold by it in substantially the manner described under the caption “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus, the Prospectus, the French Listing Prospectus under
the caption “Purpose of the issuance and use of proceeds” and the Launch Press Release, as amended and supplemented in the Pricing Press Release as the case may be.
(l) Earnings Statement. The Company will make
generally available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company
commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder; provided, however, that the requirements of this Section 3(l)
shall be satisfied to the extent that such earnings statement is available on EDGAR.
(m) Continued Compliance with Securities Laws. The
Company will comply with the Securities Act, the Exchange Act and applicable French laws and regulations so as to permit the completion of the distribution of the Offered Securities as contemplated by this Agreement, the Registration
Statement, the F-6 Registration Statement, the Time of Sale Prospectus, the Prospectus, the French Listing Prospectus and the Offering Press Releases. Without limiting the generality of the foregoing, the Company will, during the period when a
prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and
Nasdaq all reports and documents required to be filed under the Exchange Act.
(n) Listing. The Company will use its best
efforts to list the Firm Shares and the Underlying Shares on Euronext. No action is required in connection with the offered ADSs being listed on Nasdaq.
(o) Company to Provide Copy of the Prospectus in Form
That May be Downloaded from the Internet. If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an “electronic
Prospectus” to be used by the Underwriters in connection with the offering and sale of the Offered Securities. As used herein, the term “electronic Prospectus” means a form of Time of Sale Prospectus, and any amendment or supplement
thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and
purchasers of the Offered Securities; (ii) it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image
material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format,
satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as
a whole and for on-line time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an
undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus.
(p) Agreement Not to Offer or Sell Additional Shares.
During the period commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as
extended as described below, being referred to herein as the “Lock-up Period”), the Company will not, without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly:
(i) sell, offer to sell, contract to sell or lend any ADSs, Ordinary Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange
Act) or liquidate or decrease any “call equivalent position” (as defined in Rule 16a-1(b) under the Exchange Act) of any ADSs, Ordinary Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any ADSs, Ordinary
Shares or Related Securities; (iv) in any other way transfer or dispose of any ADSs, Ordinary Shares or Related Securities; (v) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of
ownership of any ADSs, Ordinary Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any ADSs, Ordinary Shares or Related Securities; (vii) file
any registration statement under the Securities Act in respect of any ADSs, Ordinary Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered ADSs); or (viii) publicly announce the intention to do any of
the foregoing; provided, however, that the Company may (A) effect the transactions contemplated hereby and issue ADSs or Ordinary Shares to JJDC in connection with the Strategic Offering, (B) issue ADSs or Ordinary Shares or grant free
shares, options or warrants (including founders’ share warrants (bons de souscription de parts de créateur d’entreprise, or BSPCE), share warrants (bons de souscription d’actions, or BSA) and stock options (options de souscription
d’actions) to purchase ADSs or Ordinary Shares, or procure the issuance of ADSs or Ordinary Shares upon exercise of options or warrants (including BSPCE, BSA and stock options)), pursuant to any available shareholder resolution authorizing the
issuance of such ADSs or Ordinary Shares in connection with any employee or non-employee director or management benefit, stock option, warrant plan, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of
Sale Prospectus, the Prospectus and the French Listing Prospectus, (C) file a registration statement on Form S-8 to register ADSs or Ordinary Shares issuable pursuant to the terms of a stock option, stock bonus or other similar stock plan or
arrangement described in the Registration Statement, Time of Sale Prospectus, the Prospectus and the French Listing Prospectus; (D) issue ADSs or Ordinary Shares in connection with any joint venture, commercial or collaborative relationship or the
acquisition or license by the Company of the securities, business, property or other assets of another person or entity or pursuant to any employee benefit plan as assumed by the Company in connection with any such acquisition; provided, however,
that in the case of clause (D), (x) such ADSs or Ordinary Shares shall not in the aggregate exceed 7.5% of the Company’s outstanding share capital immediately following the consummation of the offering of the Offered Securities contemplated by this
Agreement and (y) the recipients thereof provide to the Representatives, on behalf of the Underwriters, a signed agreement substantially in the same form as the Lock-Up Agreement on Exhibit E hereto; and (E) file a prospectus with the
Commission related to an at-the-market sales program and issue and sell ADSs thereunder, provided that such prospectus may only be filed at least 30 days after the date of the Final Prospectus Supplement.
For purposes of the foregoing, “Related Securities” shall mean
any options or warrants or depositary receipts evidencing ADSs or Ordinary Shares or other rights to acquire ADSs or Ordinary Shares or any securities exchangeable or exercisable for or convertible into ADSs or Ordinary Shares, or to acquire other
securities or rights ultimately exchangeable or exercisable for, or convertible into, ADSs or Ordinary Shares.
(q) Future Reports to the Representatives. During
the period of five years hereafter, the Company will furnish to each of the Representatives at their respective notice address provided in Section 15: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the
Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders’ equity and cash flows for the year then ended and the opinion thereon of the Company’s independent public or certified
public accountants; (ii) as soon as practicable after the filing thereof, copies of each Annual Report on Form 20-F, Report on Form 6-K or other report filed by the Company with the Commission or any securities exchange; and (iii) as soon as
available, copies of any report or communication of the Company furnished or made available generally to holders of its share capital; provided, however, that the requirements of this Section 3(q) shall be satisfied to the extent that such
reports, statements, communications, financial statements or other documents are available on EDGAR.
(r) Investment Limitation. The Company shall not
invest or otherwise use the proceeds received by the Company from its sale of the Offered Securities in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.
(s) No Stabilization or Manipulation; Compliance with
Regulation M. The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered
Securities or any reference security with respect to the Offered Securities, whether to facilitate the sale or resale of the Offered Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable
provisions of Regulation M. Neither the Company, nor any of its subsidiaries, nor any person acting on its or their behalf (other than the Underwriters with respect to whom the Company makes no such undertaking) will take, directly or indirectly, any
action designed to cause or to result in, or that has constituted or that might reasonably be expected to cause or result in, the stabilization of the Offered Securities in violation of applicable European Union or French laws or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Offered Securities.
(t) Enforce Lock-Up Agreements. During the
Lock-up Period, the Company will enforce all agreements between the Company and any of its security holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of ADSs, Ordinary Shares or Related Securities or any of the
other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer agent, to the extent permitted under applicable law, to place stop transfer restrictions upon any such
securities of the Company that are bound by such “lock-up” agreements for the duration of the periods contemplated in such agreements.
(u) Company to Provide Interim Financial Statements.
The Company will furnish the Underwriters, as soon as practicable after they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by
the most recent financial statements appearing in the Registration Statement and the Prospectus, provided that such obligation should terminate upon the later of (i) the Option Closing Date or (ii) the expiration of Underwriters’ option to purchase
Option ADSs, provided that no such interim financial statements shall be required to be prepared solely as a result of this Section 3(u).
(v) Deposit Agreement. On or prior to the First
Closing Date and the Option Closing Date, as applicable, the Company agrees (i) to deposit Shares with the Depositary in accordance with the provisions of the Deposit Agreement and will otherwise comply with the Deposit Agreement so that ADRs
evidencing the Offered ADSs will be executed (and, if applicable, countersigned) and issued by the Depositary against receipt of such Shares and delivered to the Underwriters at such Closing Date and (ii) to otherwise comply with the terms of the
Deposit Agreement, including without limitation, the covenants set forth in the Deposit Agreement.
(w) Tax Indemnity. The Company will indemnify and
hold harmless the Underwriters against any transaction, documentary, stamp, capital or other issuance, registration, transaction, transfer or withholding tax or duty (including any financial transaction tax as set out in Article 235 ter ZD of the Code
général des impôts), including any interest, penalties and additions to tax, that may be payable by or on behalf of the Underwriters on (i) the creation, issuance, delivery and sale of the Offered Securities, the issuance of the ADSs, and the
delivery of the Offered Securities to or for the account of the Underwriters; (ii) the purchase from the Company, and the initial sale and delivery by the Underwriters, of the Offered Securities to purchasers thereof; (iii) the holding or transfer of
the Offered Securities; (iv) the deposit of the Ordinary Shares with the Depositary and the issuance and delivery of the ADRs evidencing the ADSs; or (v) the execution, delivery and consummation of this Agreement or the Deposit Agreement or any other
document to be furnished hereunder. Moreover, the Company will, in addition to any amount payable by it pursuant to Section 3(w) and Section 4 (and at the same time as paying that amount), pay any VAT, sale or similar tax payable in addition to that
amount.
(x) Transfer Agent. The Company agrees to
maintain a transfer agent and registrar (services titres) for the Ordinary Shares.
(y) Amendments and Supplements to Permitted Section
5(d) Communications. If at any time following the use of any Permitted Section 5(d) Communication during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule), there occurred or occurs an event or development as a result of which such Permitted Section 5(d) Communication included or would include an untrue statement of a
material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the
Representatives and will promptly amend or supplement, at its own expense, such Permitted Section 5(d) Communication to eliminate or correct such untrue statement or omission.
(z) Emerging Growth Company Status. The Company
will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) the time when a prospectus relating to the Offered Securities is not required by the Securities Act to be delivered
(whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) and (ii) the expiration of the Lock-Up Period (as defined herein).
(aa) Euronext Notices. The Company will as soon as
practicable, before or after the First Closing Date and in any event within any prescribed period of time, give such notices to, or make such filings with, Euronext or other agencies or bodies, as shall be required under any applicable laws or
regulations in connection with this offering.
(bb) Sales Taxes. If the performance by the
Underwriters of any of their obligations under this Agreement shall represent for VAT purposes under any applicable law the making by the Underwriters of any supply of goods or services to the Company (to the extent applicable), the Company shall pay
to the Underwriters, in addition to the amounts otherwise payable by the Company pursuant to this Agreement, an amount equal to the VAT chargeable on any such supply of goods and services provided that the Underwriters have issued the Company with an
appropriate VAT invoice in respect of the supply to which the payment relates. Where a sum (a “Relevant Sum”) is paid or reimbursed to the Underwriters pursuant to this Agreement in respect of any cost, expense or other amount and that cost,
expense or other amount includes an amount in respect of irrecoverable VAT (the “VAT Element”) which has been certified as such by the Underwriters (acting reasonably), then the Company, to the extent applicable, shall, in addition, pay an
amount equal to the VAT Element to the Underwriters. For the purposes of this Agreement, “VAT” means any French or non-French value added tax, sales tax or similar tax payable in addition to the price of any supply of goods or services.
The Representatives, on behalf of the several Underwriters, may, in
their sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance.
Section 4. Payment of Expenses.
The Company agrees to pay all costs, fees and expenses incurred in connection with the
performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Offered Securities (including all printing and engraving
costs), (ii) all fees and expenses of the registrar and transfer agent of the Ordinary Shares, (iii) all fees and expenses of the Depositary related to the Offered Securities, (iv) all VAT, issue, transfer and other stamp taxes in connection with the
issuance and sale of the Offered Securities to the Underwriters, (v) all fees and expenses of the Company’s counsels, independent public or certified public accountants and other advisors, (vi) all costs and expenses incurred in connection with the
preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the F-6 Registration Statement, the Time of Sale Prospectus, the
Prospectus, the Information Documents, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section 5(d) Communication, and all amendments and supplements
thereto, and this Agreement, (vii) all filing fees, attorneys’ fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any
part of the Offered Securities for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a “Blue Sky Survey” or memorandum and a
“Canadian wrapper”, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (viii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the
rules and regulations of FINRA related to the Underwriters’ participation in the offering and distribution of the Offered Securities, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters (such
fees and expenses of counsel, together with the fees and expenses described in clause (vii) above, not to exceed $35,000 in the aggregate), (ix) the costs and expenses of the Company relating to investor presentations on any “road show”, any
Permitted Section 5(d) Communication or any Section 5(d) Oral Communication undertaken in connection with the offering of the Offered Securities, including, without limitation, expenses associated with the preparation or dissemination of any
electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging
expenses of the representatives, employees and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered, if approved by the Company, in connection with the road show (with the remaining 50% of the cost of such
aircraft to be paid by the Underwriters), (ix) the fees and expenses associated with the inclusion of the Offered ADSs for listing on Nasdaq and with listing the Firm Shares and all Underlying Shares on Euronext and (x) all other fees, costs and
expenses of the nature referred to under the caption “Expenses Relating to this Offering” in the Registration Statement. Except as provided in this Section 4 or in Section 3, Section 7, Section 9 or Section 10 hereof, the Underwriters shall pay their
own expenses, including the fees and disbursements of their counsels.
Section 5. Covenants of the Underwriters.
Each Underwriter severally and not jointly covenants with the Company
not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but
for such actions, be required to be filed by the Company under Rule 433(d).
Section 6. Conditions of the Obligations of the
Underwriters. The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Securities as provided herein on the First Closing Date and, with respect to the Option ADSs, the Option Closing Date, shall be
subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Option ADSs, as of the Option
Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:
(a) Comfort Letter and Lettre de Fin de Travaux.
On the date hereof, the Representatives shall have received from Ernst & Young et Autres, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant’s “comfort letters” to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin),
with respect to the audited and certain financial information contained in the Registration Statement, the Time of Sale Prospectus and each free writing prospectus, if any. On the date hereof, the Representatives shall have received a copy of the lettre
de fin de travaux delivered to the Company by Ernst & Young et Autres on the Universal Registration Document and such lettre de fin de travaux shall not contain any reservation, observation or warning.
(b) Compliance with Registration Requirements; No
Stop Order; No Objection from FINRA. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Option ADSs purchased after the First Closing Date, the Option Closing Date:
(i) The Company shall have filed the Prospectus with the
Commission (including the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act.
(ii) No stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment to the Registration Statement or the F-6 Registration Statement or any post-effective amendment to the F-6 Registration Statement shall be in effect, and no proceedings for such purpose shall
have been instituted or threatened by the Commission.
(iii) No order preventing or suspending the use of the French
Listing Prospectus shall have been issued by the AMF, nor shall any challenge to the approval of the AMF on the French Listing Prospectus have been filed with any French court, with the exclusion of any shallow claim.
(iv) If a filing has been made with FINRA, FINRA shall have
raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.
(c) No Material Adverse Change. For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Option ADSs purchased after the First Closing Date, the Option Closing Date in the judgment of the Representatives there shall not
have occurred any Material Adverse Change.
(d) Opinion of U.S. Counsel for the Company. On
each of the First Closing Date and the Option Closing Date, the Representatives shall have received the opinion of Jones Day, U.S. counsel for the Company, dated as of such date, substantially in the form attached hereto as Exhibit A.
(e) Opinion of French Counsel for the Company. On
the First Closing Date and the Option Closing Date, the Representatives shall have received the opinion of Jones Day, French counsel for the Company, dated as of such date, substantially in the form attached hereto as Exhibit B.
(f) Opinion of Intellectual Property Counsel for the
Company. On each of the First Closing Date and the Option Closing Date, the Representatives shall have received the opinions of Dreyfus & Associates and Becker & Associates, counsel for the Company with respect to intellectual property
matters, dated as of such date, in the form attached hereto as Exhibits C-1 and C-2 and to such further effect as the Representatives shall reasonably request.
(g) Opinion of Counsel for the Depositary. On
each of the First Closing Date and the Option Closing Date, the Representatives shall have received the opinion of Patterson Belknap Webb & Tyler LP, counsel for the Depositary, dated as of such date, in the form attached hereto as Exhibit D
and to such further effect as the Representatives shall reasonably request.
(h) Opinion of U.S. Counsel for the Underwriters.
On each of the First Closing Date and the Option Closing Date the Representatives shall have received the opinion of Cooley LLP, U.S. counsel for the Underwriters in connection with the offer and sale of the Offered Securities, in form and substance
satisfactory to the Underwriters, dated as of such date.
(i) Opinion of French Counsel for the Underwriters.
On each of the First Closing Date and the Option Closing Date the Representatives shall have received the opinion of Gide Loyrette Nouel A.A.R.P.I., French counsel for the Underwriters in connection with the offer and sale of the Offered Securities,
in form and substance satisfactory to the Underwriters, dated as of such date.
(j) Officers’ Certificate. On each of the First
Closing Date and the Option Closing Date, the Representatives shall have received a certificate executed by the Chairman of the Executive Board and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section
6(b)(ii) and further to the effect that:
(i) for the period from and including the date of this
Agreement through and including such date, there has not occurred any Material Adverse Change;
(ii) the representations, warranties and covenants of the
Company set forth in Section 1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and
(iii) the Company has complied with all the agreements
hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.
(k) Bring-down Comfort Letter and Lettres de Fin
de Travaux. On each of the First Closing Date and the Option Closing Date the Representatives shall have received from Ernst & Young et Autres, independent registered public accountants for the Company, a letter dated such date, in
form and substance satisfactory to the Representatives, which letter shall: (i) reaffirm the statements made in the letter furnished by them pursuant to Section 6(a), except that the specified date referred to therein for the carrying out of
procedures shall be no more than three business days prior to the First Closing Date or the Option Closing Date, as the case may be; and (ii) cover certain financial information contained in the Prospectus. On the First Closing Date, the
Representatives shall have received a copy of the lettres de fin de travaux delivered to the Company by Ernst & Young et Autres and such lettres de fin de travaux shall not contain any reservation, observation or warning.
(l) Lock-Up Agreements. On or prior to the date
hereof, the Company shall have furnished to the Representatives an agreement in the form of Exhibit E hereto from each of the persons listed on Exhibit F hereto, and each such agreement shall be in full force and effect on each of the
First Closing Date and the Option Closing Date.
(m) Rule 462(b) Registration Statement. In the
event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have
become effective automatically upon such filing.
(n) Approval of Listing. At the First Closing
Date, the Firm Shares and the Underlying Shares shall have been approved for listing on Euronext, in each case subject only to official notice of issuance.
(o) Certificat du dépositaire. On the
First Closing Date, once it has received the funds corresponding to the subscription of the applicable Offered Securities and/or irrevocably pre-matched settlement instructions with Jefferies, as a Representative of the Underwriters for purposes of
settlement and delivery of the Offered Securities, as the case may be, the Registrar shall issue one depositary certificate (certificat du dépositaire) provided for by Article L. 225-146 of the French Commercial Code, relating to the capital
increase of the Company resulting from the subscription of the Firm Securities (and, as the case may be, the Option ADSs), and shall send a copy thereof to the Company and the Representatives.
(p) Deposit Agreement. The Deposit Agreement
shall be in full force and effect. The Depositary shall have delivered to the Company certificates satisfactory to the Underwriters evidencing the deposit with the Depositary or its nominee of the Underlying Shares being so deposited against issuance
of ADRs evidencing the ADSs to be delivered by the Company at the First Closing Date or the Option Closing Date, as the case may be, and the execution, countersignature (if applicable), issuance and delivery of ADRs evidencing such ADSs pursuant to
the Deposit Agreement.
(q) Investor Letter. The Underwriters and
the Company shall have received an investor letter substantially in the form of either Exhibit G-1 or Exhibit G-2, as applicable, from each prospective investor, attesting in particular their qualification in the category defined by the
Company’s combined shareholders’ meeting held on June 27, 2023, pursuant to its 24th resolution, and such letter shall be in full force and effect.
(r) Chief Financial Officer’s Certificate. On
the date of this Agreement and on each of the First Closing Date and the Option Closing Date, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of
its Chief Financial Officer with respect to certain financial data contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus, in form and substance reasonably satisfactory to the Representatives.
(s) Additional Documents. On or before each of
the First Closing Date and the Option Closing Date, the Representatives and counsels for the Underwriters shall have received such customary information, documents and opinions as they may reasonably request for the purposes of enabling them to pass
upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained.
If any condition specified in this Section 6 is not satisfied when and
as required to be satisfied, this Agreement may be terminated by the Representatives by written notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Option ADSs, at any time on or
prior to the Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such termination.
Section 7. Reimbursement of Underwriters’ Expenses. If
this Agreement is terminated by the Representatives pursuant to Section 6, Section 11 or Section 12, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated because of any refusal, inability or
failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with
respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered
Securities, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges, provided, however, that in the event any such termination is effected after the First Closing
Date but prior to the Option Closing Date with respect to the purchase of any Option ADSs, the Company shall only reimburse the Underwriters for all of their out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the
Underwriters, incurred after the First Closing Date in connection with the proposed purchase of any such Option ADSs. For the avoidance of doubt, it is understood that the Company will not pay or reimburse any costs, fees or expenses incurred by any
Underwriter that defaults on its obligations to purchase the Offered Securities.
Section 8. Effectiveness of this Agreement. This
Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
Section 9. Indemnification.
(a) Indemnification of the Underwriters. The
Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any
loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state
statutory law or regulation, or the laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the
written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (A) (i) any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement or the F-6 Registration Statement, or any amendment to the Registration Statement or the F-6 Registration Statement, or the omission or alleged omission to state therein a material fact required to be
stated in the Registration Statement or the F-6 Registration Statement or necessary to make the statements in the Registration Statement or the F-6 Registration Statement not misleading; or (ii) any untrue statement or alleged untrue statement of a
material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Section 5(d)
Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which
they were made, not misleading; (iii) any untrue statement or alleged untrue statement of a material fact contained in the Information Documents, or the omission or alleged omission to state therein a material fact required to be stated in the
Information Documents or necessary to make the statements in the Information Documents not misleading; or (iv) any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the
Offered Securities or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i) or (ii) above; and to reimburse each
Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all reasonable expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such
affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the
foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made
in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, the F-6 Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, the Information Documents, any such free writing prospectus, any Marketing Material, any Section 5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that
the only such information consists of the information described in Section 9(b) below. The indemnity agreement set forth in this Section 9(a) shall be in addition to any liabilities that the Company may otherwise have.
(b) Indemnification of the Company and its Board
Members and Officers. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its supervisory board members, executive board members, each of its officers who signed the Registration Statement and
the F-6 Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such board
member, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement
is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement or the F-6 Registration Statement, or any amendment to the Registration Statement or the F-6 Registration Statement, or the omission or alleged omission to state therein a material
fact required to be stated in the Registration Statement or the F-6 Registration Statement or necessary to make the statements in the Registration Statement or the F-6 Registration Statement not misleading; (ii) any untrue statement or alleged untrue
statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any
Section 5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which
they were made, not misleading or (iii) any untrue statement or alleged untrue statement of a material fact contained in the Information Documents, or the omission or alleged omission to state therein a material fact required to be stated in the
Information Documents or necessary to make the statements in the Information Documents not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made
in the Registration Statement, the F-6 Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Section 5(d) Written Communication or the Prospectus (or any such amendment or supplement) or
the Information Documents, in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration
Statement, the F-6 Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Information Documents, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities
Act, any Section 5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence of the third paragraph under the caption “Underwriting,” the sixth paragraph under the
caption “Underwriting,” the first paragraph and table under the caption “Underwriting—Commission and Expenses,” the paragraphs under the caption “Underwriting—Stabilization,” and the first sentence under the caption “Underwriting—Electronic
Distribution” in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.
(c) Notifications and Other Indemnification
Procedures. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this
Section 9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent
the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any
such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly
with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory
to such indemnified party; provided, however, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between
the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those
available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or
parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be
liable to such indemnified party under this Section 9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in
accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the
indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section 9(a)
above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above)) or (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the
reasonable fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred upon receipt from the indemnified party of a written request for payment thereof accompanied by a written statement with
reasonable supporting detail of such fees and expenses.
(d) Settlements. The indemnifying party under
this Section 9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for reasonable fees and expenses of counsel as contemplated by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered
into more than 45 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No
indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified
party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on
claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.
Section 10. Contribution. If the indemnification provided
for in Section 9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the
statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the
other hand, in connection with the offering of the Offered Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities pursuant to this Agreement
(before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering
price of the Offered Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.
The amount paid or payable by a party as a result of the losses, claims,
damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section 9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending
any action or claim. The provisions set forth in Section 9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 10; provided, however, that no additional notice shall
be required with respect to any action for which notice has been given under Section 9(c) for purposes of indemnification.
The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to this Section 10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
considerations referred to in this Section 10.
Notwithstanding the provisions of this Section 10, no Underwriter shall
be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this
Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on Schedule A. For purposes of this Section 10, each affiliate, director, officer, employee and
agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each member of the supervisory board of the
Company, each member of the executive board of the Company, each officer of the Company who signed the Registration Statement or the F-6 Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities
Act and the Exchange Act shall have the same rights to contribution as the Company.
Section 11. Default of One or More of the Several
Underwriters. If, on the First Closing Date or the Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and
the aggregate number of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Securities to be purchased on such date, the
Representatives may make arrangements satisfactory to the Company for the purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be
obligated, severally and not jointly, in the proportions that the number of Firm Securities set forth opposite their respective names on Schedule A bears to the aggregate number of Firm Securities set forth opposite the names of all such
non-defaulting Underwriters, or in such other proportions as may be specified by the applicable Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Securities and the aggregate number of Offered Securities
with respect to which such default occurs exceeds 10% of the aggregate number of Offered Securities to be purchased on such date, and arrangements satisfactory to the applicable Representatives and the Company for the purchase of such Offered
Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall at all times be effective
and shall survive such termination. In any such case either the applicable Representatives or the Company shall have the right to postpone the First Closing Date or the Option Closing Date, as the case may be, but in no event for longer than seven
days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.
As used in this Agreement, the term “Underwriter” shall be deemed
to include any person substituted for a defaulting Underwriter under this Section 11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement.
Section 12. Termination of this Agreement. Prior
to the purchase of the Firm Securities by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i) trading or quotation in any of the Company’s securities
shall have been suspended or limited by the Commission or by the Nasdaq, the AMF and/or Euronext or trading in securities generally on either the Nasdaq, the New York Stock Exchange or Euronext shall have been suspended or limited, or minimum or
maximum prices shall have been generally established on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of United States federal, New York or French authorities; (iii) there shall have occurred any
outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States, French or international financial markets, or any substantial change or development involving a prospective substantial
change in the United States’, France’s or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Securities in the manner and on
the terms described in the Time of Sale Prospectus, the Prospectus, the French Listing Prospectus or the Offering Press Releases or to enforce contracts for the sale of securities; (iv) in the judgment of the Representatives there shall have occurred
any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the
business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company
shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any Underwriter to the Company; provided, however, that the provisions of Section 9 and Section 10 shall
at all times be effective and shall survive such termination.
Section 13. No Advisory or Fiduciary Relationship. The
Company acknowledges and agrees that (a) the purchase and sale of the Offered Securities pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts and commissions, is an
arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and
has been acting solely as a principal and is not the agent or fiduciary of the Company or its shareholders, creditors or employees, or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of
the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the
Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that
differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax
advisors to the extent it deemed appropriate.
Section 14. Representations and Indemnities to Survive
Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary
notwithstanding, will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.
Section 15. Notices. All communications hereunder shall
be in writing and shall be mailed, emailed, hand delivered or telecopied and confirmed to the parties hereto as follows:
| |
If to the Representatives: |
Jefferies LLC |
| |
|
520 Madison Avenue |
| |
|
New York, New York 10022 |
| |
|
Facsimile: (646) 619-4437 |
| |
|
Attention: General Counsel |
| |
|
|
| |
|
Leerink Partners LLC |
| |
|
1301 Avenue of the Americas, 12th Floor |
| |
|
New York, New York 10019 |
| |
|
Email: stuart.nayman@leerink.com |
| |
|
Attention: Stuart Nayman, Esq. |
| |
|
|
| |
|
Guggenheim Securities, LLC |
| |
|
330 Madison Avenue |
| |
|
New York, New York 10017 |
| |
|
Facsimile: (212) 658-9689 |
| |
|
Attention: Head of Equity Capital Markets |
| |
|
|
| |
with copies to: |
Cooley LLP |
| |
|
11951 Freedom Drive |
| |
|
14th Floor |
| |
|
Reston, Virginia 20190 |
| |
|
Facsimile: (703) 456-8100 |
| |
|
Attention: Brian Leaf and Katie Kazem |
| |
|
|
| |
|
Gide Loyrette Nouel A.A.R.P.I. |
| |
|
15, rue de Laborde |
| |
|
75008 Paris, France |
| |
|
Facsimile: +33 1 40 75 37 68 |
| |
|
Attention: Arnaud Duhamel |
| |
|
|
| |
If to the Company: |
Nanobiotix S.A. |
| |
|
60, rue de Wattignies |
| |
|
75012 Paris, France |
| |
|
Facsimile: +33 1 40 26 04 44 |
| |
|
Attention: Laurent Levy |
| |
|
|
| |
with copies to: |
Jones Day |
| |
|
250 Vesey Street |
| |
|
New York, New York 10281 |
| |
|
Facsimile: (212) 755-7306 |
| |
|
Attention: Peter Devlin |
| |
|
|
| |
|
Jones Day |
| |
|
2, rue Saint-Florentin |
| |
|
75001 Paris, France |
| |
|
Facsimile: +33 1 56 59 39 38 |
| |
|
Attention: Renaud Bonnet |
Any party hereto may change the address for receipt of communications by
giving written notice to the others.
Section 16. Successors. This Agreement will inure
to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section
9 and Section 10, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Offered Securities as such from any of the Underwriters
merely by reason of such purchase.
Section 17. Partial Unenforceability. The invalidity or
unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason
determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.
Section 18. Recognition of the U.S. Special Resolution Regimes.
A. In the event that any Underwriter that is a Covered
Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer
would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.
B. In the event that any Underwriter that is a Covered
Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater
extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.
For purposes of this Agreement, (A) “BHC Act Affiliate” has the meaning assigned to
the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right”
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
Section 19. Governing
Law Provisions; Currency Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or
proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New
York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings
instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or
document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of
any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. The Company and each other party not located in the United States has irrevocably appointed CT Corporation, which currently maintains an office at 28 Liberty Street, 42nd Floor, New York, New York 10005, United States of America, as
its agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted in any state or federal court in the Borough of Manhattan in the City of New York, United States of America.
With respect to any Related Proceeding, each party irrevocably waives,
to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be
entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity
at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.
The obligations of the Company pursuant to this Agreement in respect of
any sum due to any Underwriter shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first business day, following receipt by any Underwriter of any sum adjudged to be so due in such other
currency, on which such Underwriter may in accordance with normal banking procedures purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such Underwriter in United
States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify such Underwriter against such loss. If the United States dollars so purchased are greater than the sum originally due to such
Underwriter hereunder, such Underwriter agrees to pay to the Company an amount equal to the excess of the dollars so purchased over the sum originally due to such Underwriter hereunder.
All payments made by the Company under this Agreement, if any, will be
made without withholding or deduction for or on account of any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed or levied by or on behalf of any taxing authority unless
the Company is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts as will result, after such withholding or deduction, in the
receipt by each Underwriter of the amounts that would otherwise have been receivable in respect thereof if no withholding or deduction had been made. If any such taxes, duties, assessments or charges are required to be withheld or deducted, the
Company will promptly (and in any event within the specified time limit) pay to the relevant tax authority the amount so withheld or deducted and provide the Underwriters with evidence of such payment.
Section 20. Affiliates. The Representatives and the
Underwriters may provide their services through or in conjunction with one or more of their affiliates, and references in this Agreement to the “Representatives” and the “Underwriters” shall, save where the context otherwise requires, include any
such affiliates.
Section 21. General Provisions. This Agreement constitutes
the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two
or more counterparts, each one of which shall be an original, and delivered by electronic means, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in
writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only
and shall not affect the construction or interpretation of this Agreement.
Each of the parties hereto acknowledges that it is a sophisticated
business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions of Section 10, and is fully
informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of Section 9 and Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and
its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus, the Prospectus and the Information Documents (and any
amendments and supplements to the foregoing), as contemplated by the Securities Act, the Exchange Act and applicable French laws and regulations.
Section 22. Product Governance Rules. Solely for the
purposes of the requirements of Article 9(8) of the MIFID Product Governance rules under EU Delegated Directive 2017/593 (the “Delegated Directive”) regarding the mutual responsibilities of manufacturers under the Product Governance
requirements contained within: (a) MiFID II; (b) Articles 9 and 10 of the Delegated Directive; and (c) local implementing measures (the “Product Governance Rules”) (i) each manufacturer acknowledges to each other manufacturer that it
understands the responsibilities conferred upon it under the Product Governance Rules relating to each of the product approval process, the target market and the eligible distribution channels for dissemination of the ADSs, the related information
set out in the Prospectus in connection with the ADSs and the requirement to carry out a product approval process; and (ii) the Underwriters and the Company note the application of the Product Governance Rules and acknowledge the target market and
distribution channels identified as applying to the ADSs by the manufacturers and the related information set out in the Prospectus in connection with the ADSs.
If the foregoing is in accordance with your understanding of our
agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.
| |
Very truly yours, |
| |
|
|
| |
NANOBIOTIX S.A. |
| |
|
|
| |
By: |
/s/ Laurent Levy |
| |
|
Name: Laurent Levy |
| |
|
Title: Chairman of the Executive Board |
[Signature Page to Underwriting Agreement]
The foregoing Underwriting Agreement is hereby confirmed and accepted by
the Representatives in New York, New York as of the date first above written.
| JEFFERIES LLC |
|
| |
|
|
| LEERINK PARTNERS LLC |
|
| |
|
|
| GUGGENHEIM SECURITIES, LLC |
|
| |
|
|
| Acting individually and as Representatives |
|
| of the several Underwriters named in |
|
| the attached Schedule A. |
|
| |
|
|
| JEFFERIES LLC |
|
| |
|
|
| By: |
/s/ Charlie Glazer |
|
| |
Name: Charlie Glazer |
|
| |
Title: Managing Director |
|
| |
|
|
| LEERINK PARTNERS LLC |
|
| |
|
|
| By: |
/s/ Gabriel P. Cavazos |
|
| |
Name: Gabriel P. Cavazos |
|
| |
Title: Senior Managing Director |
|
| |
|
|
| GUGGENHEIM SECURITIES, LLC |
|
| |
|
|
| By: |
/s/ Ronald Gerber |
|
| |
Name: Ronald Gerber |
|
| |
Title: Senior Managing Director |
|
[Signature Page to Underwriting Agreement]
Schedule A
| Name of Underwriters |
Total Number of Firm Securities
to be Purchased (Expressed as
a number of Ordinary Shares)
|
|
| Jefferies LLC |
2,351,635 |
|
| Leerink Partners LLC |
2,071,678 |
|
| Guggenheim Securities, LLC |
1,175,817 |
|
| Total |
5,599,130 |
|
Schedule B
Free Writing Prospectuses Included in the Time of Sale Prospectus
|
1. |
Free Writing Prospectuses |
|
a. |
Launch Press Release, issued by the Company on November 1, 2023; and |
|
b. |
Pricing Press Release, issued by the Company on November 2, 2023. |
|
2. |
Pricing information orally conveyed by the Underwriters: |
|
a. |
Offering price per ADS: $5.36 |
|
b. |
Offering price per Ordinary Share €5.07 |
|
c. |
Number of Firm ADS: 3,106,907 |
|
d. |
Number of Option ADSs: 839,869 |
|
e. |
Number of Firm Shares: 2,492,223 |
|
f. |
As of September 30, 2023, the Company has cash and cash equivalents balance of €38.7 million (unaudited). The Company believes that the net proceeds from the Global
Offering and the Concurrent Private Placement, together with its cash and cash equivalents, will be sufficient to meet its working capital requirements at least for the twelve next months, and, specifically, to the end of the third quarter
2025, and, assuming the receipt from Janssen Pharmaceutica NV (‘‘Janssen’’) of the first milestone payment under the Company’s License Agreement with Janssen, dated July 7, 2023, into the first quarter 2026. |
Schedule C
Permitted Section 5(d) Communications
None.
Exhibit E
Execution Version
Form of Lock-up Agreement
November 7, 2023
JEFFERIES LLC
LEERINK PARTNERS LLC
GUGGENHEIM SECURITIES, LLC
As Representatives of the several Underwriters
c/o JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
c/o LEERINK PARTNERS LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
c/o GUGGENHEIM SECURITIES, LLC
330 Madison Avenue, 12th Floor
New York, New York 10017
| RE: |
Nanobiotix S.A. (the “Company”) |
Ladies and Gentlemen:
The undersigned is an executive board member or
supervisory board member of the Company and/or a record or beneficial owner of ordinary shares, nominal value €0.03 per share, of the Company (“Ordinary Shares”), American Depositary Shares of the Company (“ADSs”), each
representing one Ordinary Share of the Company, or securities convertible into or exchangeable or exercisable for ADSs or Ordinary Shares. The Company proposes to conduct an underwritten registered offering of Ordinary Shares, which may be in the
form of ADSs (the “Offering”), for which Jefferies LLC, Leerink Partners LLC and Guggenheim Securities, LLC will act as representatives of the Underwriters (the “Representatives”). The undersigned recognizes that the
Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the Underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and,
at a subsequent date, in entering into an underwriting agreement (the “Underwriting Agreement”) and other underwriting arrangements with the Company with respect to the Offering.
Annex A sets forth definitions for capitalized terms
used in this letter agreement that are not defined in the body of this letter agreement. Those definitions are a part of this letter agreement.
In consideration of the foregoing, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will cause any Family Member not to), without the prior written
consent of the Representatives, which may withhold their consent in their sole discretion:
|
● |
Sell or Offer to Sell any ADSs, Ordinary Shares or Related Securities currently or hereafter owned
either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member, |
Execution Version
|
● |
make any demand for, or exercise any right with respect to, the registration under the Securities Act
of the offer and sale of any ADSs, Ordinary Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or |
|
● |
publicly announce any intention to do for her/his behalf any of the foregoing. |
The foregoing will not apply to the registration of the
offer and sale of the Ordinary Shares or ADSs in the Offering, and the sale of the Ordinary Shares or ADSs in the Offering to the Underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall
not apply to:
|
i. |
transfers or dispositions of ADSs and/or Ordinary Shares acquired in the Offering or in open market
transactions following the Offering; provided, however, that no filing or notification under the Exchange Act or other public filing or disclosure will be required or will be voluntarily made during the Lock-Up Period in connection with
such transfers or dispositions under this clause (i); |
|
ii. |
transfers of ADSs, Ordinary Shares or any Related Securities as a bona fide gift; |
|
iii. |
transfers of ADSs or Ordinary Shares or any Related Securities by will or intestate succession or to
any Family Member or to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member; |
|
iv. |
transfers by operation of law, such as transfers of ADSs or Ordinary Shares or any Related Securities
pursuant to a domestic order or negotiated divorce settlement; |
|
v. |
transfers to the Company in connection with the repurchase of ADSs or Ordinary Shares in connection
with the termination of the undersigned’s employment with the Company pursuant to contractual agreements with the Company as in effect as of the date of the final prospectus for the Offering, provided, that no filing or notification
under the Exchange Act or under Article L.621-18-2 of the French Monetary and Financial Code (Code monétaire et financier) or other applicable laws and regulations or other public filing or disclosure will be required or will be
voluntarily made during the Lock-up Period in connection with such transfers pursuant to this clause (v); |
|
vi. |
the establishment of a written trading plan for the transfer of ADSs and/or Ordinary Shares that is
intended to satisfy the requirements of Rule 10b5-1 under the Exchange Act or any analogous requirements under French law or practice for non-discretionary transfers of ADSs and/or Ordinary Shares following the date of such written plan (a
“Trading Plan”), provided that (a) such Trading Plan does not provide for the transfer of ADSs or Ordinary Shares during the Lock-up Period, and (b) to the extent a public disclosure or filing under the Exchange Act, if any, is required
of, or voluntarily made by or on behalf of, the undersigned or the Company regarding the establishment of such plan, such disclosure or filing shall include a statement to the effect that no transfer of ADSs or Ordinary Shares may be made under
such plan during the Lock-Up Period; |
|
vii. |
transfers pursuant to a bona fide third party tender offer for all outstanding ADSs and Ordinary
Shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company’s securities involving a change of control of at least 90% of the voting share capital of the Company (including, without limitation,
the entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of ADSs, Ordinary Shares or other such securities in connection with such transaction, or vote
any ADSs or Ordinary Shares or other such securities in favor of any such transaction), provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the
undersigned shall remain subject to the provisions of this letter agreement; |
|
viii. |
(a) exercises of stock options, warrants (bons de souscription d’actions), founders’ warrants
(bons de souscription de parts de créateur d’entreprise) or vesting of free shares (acquisition définitive d’actions gratuites) outstanding, described in the final prospectus for this Offering, and held by the undersigned on the
date hereof, provided that, subject to sub-clause (b) of this clause (viii), any ADSs and Ordinary Shares received upon exercise thereof shall remain subject to the provisions of this letter agreement; and (b) dispositions pursuant to
any exercise or vesting described in sub-clause (a) of this clause (viii) on a “cashless” or “net exercise” basis or otherwise for the purpose of satisfying any applicable taxes (including estimated taxes) due in connection with such exercise
or vesting. With respect to this clause (viii), no public disclosure will be voluntarily made during the Lock-Up Period in connection with such exercises, vesting and/or dispositions and to the extent any public disclosure or filing is required
by law, such disclosure or filing shall state that any disposition pursuant to sub-clause (b) of this clause (viii) is made for the purposes set forth in sub-clause (b); and |
Execution Version
|
ix. |
any action taken by the undersigned in his or her capacity as an executive or supervisory board
member in respect of primary offers and sales by the Company, which, for the avoidance of doubt, shall be subject to certain limitations set forth in the Underwriting Agreement. |
provided, however, that in the case of
any transfer or distribution pursuant to clauses (i) (in the event such subsequent resale does not occur in an open market transaction), (ii), (iii) and (iv), it shall be a condition to such transfer that:
|
● |
each donee or transferee executes and delivers to the Representatives an agreement in form and
substance satisfactory to the Representatives stating that such donee or transferee is receiving and holding such ADSs, Ordinary Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer
to Sell such ADSs, Ordinary Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such donee or transferee had been
an original signatory hereto), and |
|
● |
prior to the expiration of the Lock-up Period, no public disclosure, filing or notification under the
Exchange Act or under Article L.621-18-2 of the French Monetary and Financial Code (Code monétaire et financier) or other applicable laws and regulations or other applicable laws and regulations, by any party to the transfer (donor,
donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of ADSs, Ordinary Shares or Related Securities in connection with such transfer. |
The undersigned also agrees and consents to the entry
of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of ADSs, Ordinary Shares and/or Related Securities held by the undersigned and the undersigned’s Family Members, if any, except in compliance with the
foregoing restrictions.
With respect to the Offering only, the undersigned
waives any registration rights relating to registration under the Securities Act of the offer and sale of any ADSs, Ordinary Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to
receive notice of the Offering.
The undersigned confirms that the undersigned has not,
and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale of the Ordinary Shares and/or ADSs. The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action.
Whether or not the Offering occurs as currently
contemplated or at all depends on market conditions and other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters.
Execution Version
The undersigned hereby represents and warrants that the
undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.
This letter agreement shall be governed by, and
construed in accordance with, the laws of the State of New York.
If (i) the Company notifies the Representatives in
writing that it does not intend to proceed with the Offering, (ii) the Underwriting Agreement is not executed before November 2, 2023, or (iii) the Underwriting Agreement (other than the provisions thereof that survive termination) terminates or is
terminated prior to payment for and delivery of the shares in the Offering, then in each case, this letter agreement shall automatically, and without any action on the part of any other party, terminate and be of no further force and effect, and the
undersigned shall automatically be released from its obligations under this letter agreement.
[Signature Page Follows]
Execution Version
If an individual, please sign here:
| Signature: |
|
|
| |
|
|
| Print Name: |
|
|
| |
|
|
| Print Address: |
|
|
| |
|
|
| |
|
|
If a corporation, a limited partnership or other legal entity, please
sign here:
| Name: |
|
|
| By: |
|
|
| Its: |
|
|
| |
|
|
| By: |
|
|
| |
|
|
| Name: |
|
|
| |
|
|
| Title: |
|
|
Execution Version
Annex A
Certain Defined Terms
Used In Lock-Up Agreement
For purposes of the letter agreement to which this
Annex A is attached and of which it is made a part:
|
● |
“Call Equivalent Position” shall have the meaning set forth in Rule 16a-1(b) under the
Exchange Act. |
|
● |
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. |
|
● |
“Family Member” shall mean the spouse of the undersigned, an immediate family member of
the undersigned or an immediate family member of the undersigned’s spouse, in each case living in the undersigned’s household or whose principal residence is the undersigned’s household (regardless of whether such spouse or family member may at
the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). “Immediate family member” as used above shall have the meaning set forth in
Rule 16a-1(e) under the Exchange Act. |
|
● |
“Lock-up Period” shall mean the period beginning on the date hereof and continuing
through the close of trading on the date that is 90 days after the date of the final prospectus for the Offering. |
|
● |
“Put Equivalent Position” shall have the meaning set forth in Rule 16a-1(h) under the
Exchange Act. |
|
● |
“Related Securities” shall mean any stock options (options de souscription ou
d’achat d’actions), warrants (bons de souscription d’actions), founders’ warrants (bons de souscription de parts de créateur d’entreprise), free shares (actions gratuites) or other rights to acquire ADSs or Ordinary
Shares or any securities exchangeable or exercisable for or convertible into ADSs or Ordinary Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into ADSs or Ordinary Shares. |
|
● |
“Securities Act” shall mean the Securities Act of 1933, as amended. |
|
● |
“Sell or Offer to Sell” shall mean to: |
|
– |
sell, offer to sell, contract to sell or lend, |
|
– |
effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any
Call Equivalent Position, |
|
– |
pledge, hypothecate or grant any security interest in, or |
|
– |
in any other way transfer or dispose of, |
in each case whether effected directly or
indirectly.
|
● |
“Swap” shall mean any swap, hedge or similar arrangement or agreement that transfers,
in whole or in part, the economic risk of ownership of ADSs, Ordinary Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. |
|
● |
“Underwriters” shall mean the underwriters identified in Schedule I to the Underwriting
Agreement. |
Capitalized terms not defined in this Annex A shall
have the meanings given to them in the body of this letter agreement.
Exhibit F
Members of the Executive and Supervisory Boards
Signing Lock-up Agreement
Executive Board Members:
Laurent Levy, Ph.D.
Bart Van Rhijn
Anne-Juliette Hermant
Supervisory Board Members:
Gary Phillips
Alain Herrera, M.D.
Anne-Marie Graffin
Enno Spillner
Exhibit G-1
Form of Investor Letter (ADSs)
NANOBIOTIX S.A.
60 rue de Wattignies
75012 Paris
France
and
JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
LEERINK PARTNERS LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
GUGGENHEIM SECURITIES, LLC
330 Madison Avenue
New York, New York 10017
[•], 2023
Ladies and Gentlemen:
| RE: |
Purchase of New Shares issued by Nanobiotix S.A. |
In connection with its proposed offering of new ordinary shares (the “Ordinary Shares”) of Nanobiotix S.A., a French société anonyme à directoire et conseil de surveillance,
whose registered office is at 60 rue de Wattignies, 75012 Paris, France (the “Company”), in the context of an issuance without preferential subscription rights of Ordinary Shares (including Ordinary Shares in the form of American Depositary
Shares) reserved to a specified category of investors in accordance with the provisions of the 24th resolution of the combined shareholders’ meeting of the Company held on
June 27, 2023 (the “Reserved Offering” and such shares, the “New Shares”), the undersigned (the “Investor”) hereby represents and warrants that on behalf of itself and, if the undersigned is purchasing the New Shares for the
account or benefit of, or as a nominee, agent, fiduciary or trustee for, or in its exercise of investment discretion for, or with funds or backing provided by, or upon the instructions of, other persons, on behalf of those other persons or those
ultimate beneficial owners of the New Shares, in connection with a purchase of the New Shares under the Reserved Offering, it belongs as at the date hereof and will belong until the completion of the Reserved Offering to the category set forth in the
above-mentioned 24th resolution: natural or legal entities (including companies) trusts and investment funds or other investment vehicles whatever their form, governed by
French or foreign law, whether or not shareholders of the Company, that invest on a regular basis, or have invested (including where applicable, in the form of loans or convertible or non-convertible debt securities) at least one million euros within
the last 36 months, in the health or biotechnological sectors1.
1 i.e. ““toutes personnes physiques ou
morales (en ce compris toutes sociétés), trusts et fonds d’investissement, ou autres véhicules de placement, quelle que soit leur forme (en ce compris, sans limitation, tout fonds d’investissement ou sociétés de capital-risque, notamment tout FPCI,
FCPI ou FIP), de droit français ou étranger, actionnaires ou non de la Société, investissant à titre habituel, ou ayant investi (y compris, le cas échéant, sous forme de prêt ou de titres de créances convertibles ou non) au moins un million d’euros
au cours des 36 derniers mois, dans le secteur de la santé ou des biotechnologies”.
The Investor Letter is governed by and shall be construed in accordance with the laws of France.
Sincerely yours,
On behalf of _______________________________
By:______________________________________
Name:
Title:
|
Please indicate allocated entities
(in case of signature by management company, please indicate allocated funds,
in case of broker, please indicate allocated clients)
|
|
______________________________________
______________________________________
______________________________________
______________________________________
|
Exhibit G-2
Form of Investor Letter (Ordinary Shares)
NANOBIOTIX S.A.
60 rue de Wattignies
75012 Paris
France
and
JEFFERIES LLC
520 Madison Avenue
New York, New York 10022
LEERINK PARTNERS LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
GUGGENHEIM SECURITIES, LLC
330 Madison Avenue
New York, New York 10017
[•], 2023
Ladies and Gentlemen:
| RE: |
Purchase of New Shares issued by Nanobiotix S.A. |
In connection with its proposed offering of new ordinary shares (the “Ordinary Shares”) of Nanobiotix S.A., a French société anonyme à directoire et conseil de surveillance,
whose registered office is at 60 rue de Wattignies, 75012 Paris, France (the “Company”), in the context of an issuance without preferential subscription rights of Ordinary Shares (including Ordinary Shares in the form of American Depositary
Shares) reserved to a specified category of investors in accordance with the provisions of the 24th resolution of the combined shareholders’ meeting of the Company held on
June 27, 2023 (the “Reserved Offering” and such shares, the “New Shares”), the undersigned (the “Investor”) hereby represents and warrants that on behalf of itself and, if the undersigned is purchasing the New Shares for the
account or benefit of, or as a nominee, agent, fiduciary or trustee for, or in its exercise of investment discretion for, or with funds or backing provided by, or upon the instructions of, other persons, on behalf of those other persons or those
ultimate beneficial owners of the New Shares, in connection with a purchase of the New Shares under the Reserved Offering:
A. it belongs as at the date hereof and will belong until the completion of the Reserved Offering to the category set forth in the above-mentioned 24th resolution: natural or legal entities (including companies) trusts and investment funds or other investment vehicles whatever their form, governed by French or foreign law, whether or not shareholders of
the Company, that invest on a regular basis, or have invested (including where applicable, in the form of loans or convertible or non-convertible debt securities) at least one million euros within the last 36 months, in the health or biotechnological
sectors2; and
2 i.e. “toutes personnes physiques ou
morales (en ce compris toutes sociétés), trusts et fonds d’investissement, ou autres véhicules de placement, quelle que soit leur forme (en ce compris, sans limitation, tout fonds d’investissement ou sociétés de capital-risque, notamment tout FPCI,
FCPI ou FIP), de droit français ou étranger, actionnaires ou non de la Société, investissant à titre habituel, ou ayant investi (y compris, le cas échéant, sous forme de prêt ou de titres de créances convertibles ou non) au moins un million d’euros
au cours des 36 derniers mois, dans le secteur de la santé ou des biotechnologies”.
B. it is as at the date hereof and will be until the completion of the Reserved Offering a “qualified investor” within the meaning of Article 2(e) of the Prospectus Regulation (EU)
2017/1129.
The Investor Letter is governed by and shall be construed in accordance with the laws of France.
Sincerely yours,
On behalf of _______________________________
By:______________________________________
Name:
Title:
|
Please indicate allocated entities
(in case of signature by management company, please indicate allocated funds,
in case of broker, please indicate allocated clients)
|
|
______________________________________
______________________________________
______________________________________
______________________________________
|
Exhibit 5.1
JONES DAY
PARTNERSHIP CONSTITUEE SELON LE DROIT
DE L’OHIO, USA
AVOCATS AU BARREAU DE PARIS
2, RUE SAINT-FLORENTIN ● 75001 PARIS
TELEPHONE: (0)1.56.59.39.39 ● FACSIMILE: (0)1.56.59.39.38 ● TOQUE J 001
WWW.JONESDAY.COM
November 7, 2023
Nanobiotix S.A.
60, rue de Wattignies
75012 Paris, France
Re: 6,279,130 Ordinary Shares of Nanobiotix S.A., including
3,786,907 U.S. Offering Shares to be Delivered in the Form of 3,786,907 American Depositary Shares
Ladies and Gentlemen:
We are acting as special French counsel for Nanobiotix S.A.,
a société anonyme incorporated in the Republic of France (the “Company”), in connection with
the issuance and sale by the Company of 6,279,130 shares (the “New Shares”) of the Company’s ordinary shares,
€0.03 nominal value per share (the “Ordinary Shares”), including 3,786,907 Ordinary Shares to be delivered in
the form of an aggregate of 3,786,907 American Depositary Shares (“ADSs”), each representing one Ordinary Share, pursuant
to an Underwriting Agreement, dated as of November 2, 2023 (the “Underwriting Agreement”), by and between the Company
and Jefferies LLC, Leerink Partners LLC and Guggenheim Securities, LLC, acting as the representative of the several underwriters
named therein.
In connection with the opinions expressed herein, we have examined
such documents, records and matters of law as we have deemed relevant or necessary for purposes of such opinions. Based on the
foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that,
as of the date hereof:
1. The issuance of
the New Shares has been duly authorized; and
2. The New Shares,
when issued and delivered pursuant to the terms of the Underwriting Agreement against full payment of their subscription price,
as provided in the Underwriting Agreement, as shall be acknowledged by the certificate of the depository (certificat du dépositaire)
to be delivered by CIC Securities, will be validly issued, fully paid and non-assessable.
The term “non-assessable”, which has no recognized
meaning in French law, for the purposes of this opinion means that no present or future holder of New Shares will be subject to
personal liability, by reason of being such a holder, for additional payments or calls for further funds by the Company or any
other person after the issuance of the New Shares.
JONES DAY
In rendering the foregoing opinion, we have assumed the genuineness
of all signatures, the authenticity of all documents submitted to us as originals and the conformity to originals of all documents
submitted to us as certified or reproduced copies. We have also assumed that the resolutions authorizing the Company to issue,
offer and sell the New Shares as adopted by the combined ordinary and extraordinary meeting of shareholders and/or the supervisory
board (conseil de surveillance) and/or management board (directoire) of the Company, as applicable, are accurately reflected in
the minutes of such meetings provided to us, and remain in full force and effect.
As to facts material to the opinions and assumptions expressed
herein, we have relied upon written statements and representations of officers of the Company and others. We are members of the
Paris bar and this opinion is limited to the laws of the Republic of France as currently in effect. This opinion is subject to
the sovereign power of the French courts to interpret agreements and assess the facts and circumstances of any adjudication. This
opinion is given on the basis that it is to be governed by, and construed in accordance with, the laws of the Republic of France.
We hereby consent to the filing of this opinion as Exhibit
5.1 to the Current Report on Form 6-K, filed on the date hereof by the Company and incorporated by reference into the registration
statement on Form F-3 (File No. 333-262545) (the “Registration Statement”) filed by the Company to effect the registration
of the New Shares under the Securities Act of 1933 (the “Act”), and to the reference to Jones Day under the caption
“Legal Matters” in the prospectus constituting a part of such Registration Statement and the final prospectus supplement,
dated as of November 2, 2023, filed by the Company pursuant to Rule 424(b) under the Act on November 6, 2023, relating to the
New Shares. In giving such consent, we do not hereby admit that we are included in the category of persons whose consent is required
under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
| |
Very truly yours, |
| |
|
| |
/s/ Jones Day |
|
Nanobiotix (NASDAQ:NBTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Nanobiotix (NASDAQ:NBTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
